

# SUBJECT INDEX 1962

This index covers all reading matter in Volume 11 of *DIABETES*. Entries marked with an asterisk (\*) indicate material that appeared in the Abstracts only. Those preceded by the letter "S" refer to the Volume 11 Supplement entitled *Tolbutamide Therapy after Five Years*. The Author Index appears on page 17.

## A

- ACD. Acid-Citrate-Dextrose, 261
- ACETATE  
enzymatic method determination, \*76  
ketone bodies, conversion to, \*157  
salicylate administration effect, \*77
- ACETOACETATE, oxidation, \*353
- ACETOHEXAMIDE  
and blood sugar, \*348  
efficacy and toxicology, 83-90, \*551  
and hypoglycemia, \*552
- ACID. *See* specific acid
- ACIDOSIS, DIABETIC  
*See also* Ketoacidosis  
and beta-hydroxybutyric acid, 25-29  
and exudative cellular response, \*551  
and fetal loss, \*346  
and insulin  
dosages, 23-28  
resistance, 30  
management, \*75  
metabolism, 363, 369  
mortality, 25  
and nitrogen deficiency, \*154
- ACTH. *See* Adrenocorticotrophic hormone
- ADDISON'S DISEASE  
insulin requirement, \*548  
and sulfonylureas, \*78
- ADRENAL GLANDS  
cortex  
atrophy, 212  
and Cushing's syndrome, \*158  
and diabetic lesions, 410-411  
enlargement, 17-18, 319  
after pituitary surgery, 471  
and hyperglycemic action of glucagon, \*158  
medulla  
hypofunction in childhood hypoglycemia, 421
- ADRENALECTOMY  
and blood sugar levels, \*78  
and epinephrine, \*159  
and glucagon  
metabolism, \*248  
reaction in baboons, \*158

- and insulin  
antagonists, \*352  
response in muscle, 175  
sensitivity, \*343-344  
and retinitis, 483-485  
and retinopathy, 461-462, 485-490, 491-494
- ADRENALIN. *See* Epinephrine
- ADRENOCORTICOTROPHIC HORMONE  
and free fatty acid release, \*343, \*352  
histological effects, 402-410  
and 17-hydroxysteroid excretion, 487  
hypophosphatemia, effect on, 31  
and insulin resistance, 31-34  
lipolysis, \*246  
and phosphorylation, 31  
after pituitary surgery, 471  
and retinal microaneurysms, 18
- AGE FACTOR  
in basement membrane thickening, 9  
in blood sugar levels, \*78  
in chlorpropamide therapy, 92-94, S99-100  
in diabetes  
mortality, 66  
onset, 46-47, 61-63  
and sera proteins, 331  
in glucose tolerance, \*154  
growth trends in teens, 52, 55  
in Increment Index, S128-129  
in pregnant diabetics and tolbutamide, S100  
and working capacity, 111
- AH6848. *See* Methoxypropyl-sulfonylurea
- ALBUMIN  
free fatty acids removal, \*352  
glycocorticoid effects, 105  
and insulin  
antagonist, \*351, \*352  
resistance, \*76  
and sulfonylureas, bound, S19-24
- ALLOXAN. *See* Diabetes mellitus, alloxan-induced
- 9 ALPHA-FLUORO-11 BETA-HYDROXY-17-ALPHA-METHYL-TESTOSTERONE, and glycogen storage disease, \*547

- 9-ALPHA-FLUOROHYDROCORTISONE  
and adrenalectomy, 486  
histological effects, 402-410
- AMERICAN DIABETES ASSOCIATION  
Affiliate Associations, 81-82, 163, 259-260, 357, 456, 558  
Detection Drives, 81  
annual meetings  
Twenty-first  
Bylaws amended, 81  
new procedure for submission of abstracts, 79  
Twenty-second, 79, 161, 252-253, 445-450  
Annual Session of Delegates, 447  
The Banting Medal, 445  
business meeting, 447-450  
elections, 354  
Executive Director's report, 448-449  
memorial tributes, 445  
Nominating Committee report, 450  
registration figures, 354  
scientific sessions, 253  
special sessions, 447  
Treasurer's report, 448  
Twenty-third, 258  
submission of abstracts, 454, 554-555  
Banting Memorial Lecture, 361-370  
Board of State Governors, 555-556  
Committees (1962-63), 556-557  
contests  
essay, 80, 453-454, 555  
research, 555  
Diabetes Week, 80, 162, 258, 356, 455
- FORECAST  
Diabetes and Urinary Tract Infection, 455  
Emergency Medical Care for Diabetics, 557  
Endocrine gland series  
The Adrenals, 162  
The Pituitary, 356  
The Thyroid, 80  
Summer Camps for Diabetic Children, 162  
Urine Testing—Its Methods and Its Importance, 258  
Friedenwald Award, 82  
International Diabetes Federation  
Fifth Congress, 258, 356  
Fourth Congress, 138-143, 228-235  
proceedings, 457

## DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume 11 Supplement, 1-150

# SUBJECT INDEX 1962

## JOURNAL

### Editorials

The Case for the Routine Use of Diets High in Polyunsaturated Fat for Diabetics, 340-341

Diabetes Mellitus: Still an Inadequately Recorded Disease, 239-240

Diabetes, Overweight, and Elevated Blood Pressure, 544-545

Fact and Fancy Concerning Tracer-Determined Flux and Accumulation of Substances in Vivo, 236-239

Insulin and Protein Synthesis in Isolated Tissues, 144-146

Nicotinic Acid and Diabetes, 144

Problem of Insulin in Blood, 69-70

Steatorrhea in Diabetic Patients, 436-437

Index, 557

new procedure for abstract submission, 79

special subscription rates, 80

Lilly award, 162, 356, 454-455

In memoriam

Jolliffe, Norman, 147-149

Joslin, Elliott Proctor, 242-244

Muhlberg, William, 340-341

Reed, John Alton, 438-439

necrology, 82, 260, 357, 457, 558

new members, 81, 162, 258-259, 357, 455-456, 557-558

News Notes, 82, 163-164, 260, 357, 457, 558

personals, 260, 357, 457, 558

postgraduate programs, 81-82, 164, 257, 356, 451-453, 554, 558

publications

binders available, 80

Membership Directory, 81

"Treatment of Diabetes," 117

research fellowships, 258, 356, 455

Research Symposium, first, 554

program, 355

scientific programs, 79, 253

exhibits, 258

list of papers, 254-257

## AMINO ACIDS

and hypoglycemia after leucine, \*250

and insulin, \*342, \*348, \*442, \*546

beef-pork, 125

metabolism, \*159, S44

myocardial, \*152

protein, incorporation in, 145, \*249

## AMPUTATIONS, below-the-knee, \*346

## ANEMIA, incidence, \*344

## ANEURYSMS. See Microaneurysms

## ANOREXIA, long-term therapy, \*74

## ANOXIA

and galactose uptake, \*550

and glycolysis, \*76

## ANTIBODIES

insulin, \*151, 308, \*440

animal and human, 124-125, 416-

418, 519-526

in childhood diabetes, 122-124

circulating, \*348

and heat labile factor in gamma globulin, 188

and insulin resistance, \*347

in plasma, 527-532

properties, 519-526

and steroid therapy, 168, \*343

and tolbutamide effects, S29-30

## APPETITE, regulation, \*444

## ARGENTINA, Congress on Nutrition, 260

## ARTERIOSCLEROSIS

of choroid, 17

in Hiroshima survey, 538

nondiabetic

and retinal vascular disease, 11

## ATHEROSCLEROSIS

and beta-glucuronidase activity, 65

and cholesterol, 144

and diet, 65, \*77, 221

and glucose tolerance, \*352

and insulin, \*77

and retinal vascular reactivity, \*74, 526

## ATOMIC BOMB CASUALTY COMMISSION IN HIROSHIMA, (ABCC)

Adult Health Study, 533-534

## AZEPINAMIDE, 218-219

comparison with

chlorpropamide, S143

tolbutamide, S143

and hypercholesteremia, S70-71

and hyperlipemia, S70-71

toxicity, S144-145

## B

## BANTING AND BEST COMMEMORATIVE MEDAL, 374

## BANTING MEMORIAL LECTURE, 361-370

## BANTU

diabetes and hemochromatosis, \*251

pregnancy, diabetic

and chlorpropamide therapy, S99-100

and tolbutamide therapy, S99-100

## BASEMENT MEMBRANE

thickening

of Bowman's capsule, 293, 305

and insulin-anti-insulin complex, 314

and lumen occlusion, 293

## BELFAST, ROYAL VICTORIA HOSPITAL DIABETES CLINIC, 91

## BENEDICT'S COPPER REDUCTION TEST, 53-55

## BLINDNESS. See Retinopathy

## BLOOD

See also Blood sugar, Plasma, Serum

acetaldehyde level, 40-42

acetate, \*76

ammonia level and fetal loss, \*346

and beta-hydroxybutyric acid, 25-29

cholesterol and work tests, 114

cortisol, 487

free fatty acids, 223

galactose concentration, \*155

and galactosemia detection, \*159-160

insulin

activity, \*245

assays, 69-70

free and complex, 261-266, S34

-like activity, S46

and pancreatoduodenectomy, \*247

ketone bodies, 26, \*157

Bessman and Anderson method, 24

lactate level, 285

lipids, \*74

azepinamide effect, S71

after exercise, 113

tolbutamide effect, S70

and liver glycogen disease, \*550, \*553

oleic acid, \*549

peripheral and insulin, 506

phosphate

and metabolism, intracellular, 29

plasma

and glucose, \*549

and tracer methods, 236-238

pyruvate level, 285, \*548

tests

in healthy old people, \*154

Kent-Jones and Taylor method, 40

screening, 44-45, \*160

Stotz's method, 40

tolbutamide levels, S94

triglycerides

and work tests, 114

urea, 484, 485

nitrogen, 24

## BLOOD FLOW. See Circulation

## BLOOD GLUCOSE. See Blood sugar

## BLOOD GROUPS, and disease associations, 329

## BLOOD PRESSURE

See also Hypertension

and adrenalectomy, 488

and bacteremic shock, \*347

in diabetic retinopathy, 11-12

after gastrectomy, \*152

and hyperglycemia, \*348

and hypophysectomy, 462, 471, 477

increase and glomerulosclerosis, \*440

and insulin, \*348, 396, 421

## BLOOD SUGAR

abnormalities, \*440

after acetoexamide therapy, 87

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-164

May-June, 165-260

July-August, 261-360

September-October, 361-460

November-December, 461-562

Volume II Supplement, 1-150

after adrenal steroids administration, 32  
adrenalectomy effect, \*78  
and antibiotic drugs, \*345  
and anti-insulin serum, S26-33  
and 2, 2'-bipyridine, \*442  
and chlorothiazide, \*441  
after chlorpropamide therapy, 92  
and cortisone, 211  
in "diabeticity" index, \*442-443  
after exercise, 111-112, 114  
fasting, 45, \*78, \*154  
    in controlled diabetics, S58  
    after insulin, S44-45  
    after tolbutamide, S44-45  
after glucagon, \*73  
after growth hormone administration, 427  
hydrocortisone effect, 174  
in infants  
    of diabetic mothers, \*153  
    and tolbutamide, S95-96  
and insulin  
    antibodies, 520-522  
    dosages, 23-28  
    free, increase of, S34  
    and leucine, 399, \*552  
and liver  
    glucose activity, \*73, 270  
    glycogen disease, \*550  
maternal and fetal, 324  
in pancreatic vein, 505  
and phenethylbiguanide, \*348, \*551  
and phenformin, \*160, 284-285  
and severity of diabetes, 45  
and sulfonylureas, \*348, S61-68  
tests  
    comparison of methods, \*158  
    comparison of test results, 204-208, \*351  
    Dextrotest method, \*158  
    Folin-Malmros, S104, 534  
    Folin-Wu, 204-208  
    glucose oxidase method, 53  
    after goldthioglucose administration, 210  
    Hagedorn-Jensen, 31, 44, 202, 210, S138  
    sequential, \*245  
    Somogyi-Nelson method, 24, 49-50, 53, 87, \*154, \*158, 204-208, 426, S37, S94, S116, S135  
and thiohexamide, \*348, \*552  
and tolbutamide, \*352, S2, S70, S124-125  
    test, S97-98  
    in infants and children, S135-136  
and wound healing, \*250

# BLOOD VESSELS

See also specific sites  
alterations in diabetes, \*441  
aorta  
    insulin effect, 422-425  
arterial  
    atheromatous occlusion, \*553  
arterioles  
    hyalination, 9-11, \*440

capillary  
    microaneurysms, 4-8  
    in tissue, adipose, 383  
    and venous blood sugar, \*154  
capillovenous  
    glucose differences, \*444  
coronary artery disease, \*252, 485  
in eyes  
    hypophysectomy effect, 476-477  
    and glomerulosclerosis, 297-304  
    peripheral disease, 538  
retinal  
    nervous element support, 14  
    and oxygen inhalation, \*74  
    and retinopathy, \*252

# BONE

marrow aplasia, \*353  
necrosis in feet, \*76

# BOOK REVIEWS

Annual Review of Biochemistry, edited by J. M. Luck, 240-241  
Cardiacs and Diabetics in Industry. A Study in Work Experience, by Grace Wyshak, Leonid S. Snegireff, and Augusta F. Law, 240  
Clinical Research in Diabetes and Pregnancy, edited by Jorgen Pedersen, 545-546  
Comparative Physiology of Carbohydrate Metabolism in Heterothermic Animals, edited by A. W. Martin, 437  
Contribution à la Biochimie des Obésités Experimentales, by J. Christophe, 241  
Diabetes in an English Community, by Joan B. Walker, 241  
Diet Manual, compiled by Dietary Staff of Vanderbilt Hospital, 341  
Disease and Injury, edited by Leopold Brahdry, 149  
The Human Adrenal Gland, by Louis J. Soffer, Ralph S. Dorfman, and Jacques L. Gabrilove, 437  
Oral Treatment of Diabetes (A Clinical and Experimental Review), by Werner Creutzfeldt and Hans-Dieter Söling, 149  
The Pancreas in Human and Experimental Diabetes, by Sydney S. Lazarus and Bruno W. Volk, 546

# BOSTON CITY HOSPITAL OUT-PATIENT CLINIC, 204

# BRAIN

blood vessels  
    and yttrium implants, 482  
capillaries, dilated in diabetics, 9  
glioma, 127  
glucose and oxygen difference, \*444  
glucose permeability, 209

hypoglycemic effects, \*72-73  
hypophysectomy effect, 462  
medulloblastoma  
    and neovascularization, 130  
    trypsin digestion preparation, 126-128  
mucormycosis, \*155, \*342  
nerve palsy, \*348  
salicylates administration effect, \*77

# BRATTON AND MARSHALL PROCEDURE, S19

BRITISH DIABETIC ASSOCIATION  
chlorpropamide and placebo study, S129  
papers presented at meeting, 131, 160, 201, 290

# BRUCH'S MEMBRANE, 17

BUILD AND BLOOD PRESSURE STUDY, 52, 55, 196, 544-545

# C

## CAMP NYDA

medical problems, \*74, \*249

## CANCER

and insulin resistance, \*348  
pancreatic, 120, \*246  
tolbutamide test, \*439

## CAPE TOWN SERIES

pregnancy, diabetic  
and chlorpropamide therapy, S99-100  
and tolbutamide therapy, S99-100

## CAPILLARIES. See Blood vessels

## CARBOHYDRATES

in diet, diabetic, \*350  
and insulin deficiency, \*159  
and liver lipids, \*250  
metabolism, \*548  
    and anabolic steroid, \*549  
    in beta cells, 99  
    in healthy old people, \*154  
    in liver, 364-365  
    in newborn infants, \*153  
    in pregnant nondiabetics, \*158  
    thiazide drugs, effect of, \*251  
tolerance, 44-45, \*72  
    and chlorpropamide, S127-129  
    and hyperadrenocorticism, 171  
    after nicotinic acid, 144  
    after sulfonylureas, \*252  
    and tolbutamide, S123-126  
utilization  
    after sulfonylureas, S66  
    in young diabetics, S125-126

## CARBON DIOXIDE

in carbohydrate metabolism, 369  
glycogen synthesis effect, 367-369  
ketone bodies, \*157  
production, \*249

# DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

## CARBUTAMIDE

- alpha globulin bound, S19-22
- Bratton and Marshall procedure analysis, S19
- dose-response, 84
- and hepatic glucose release, S16-17
- and islet weight, S117
- teratogenic action in rats, S98
- thrombocytopenic effect, \*346
- toxicity, 94, 216

## CARNITINE, and fatty acid oxidation, \*160, \*248

## CASE REPORT

- Addison's disease, \*548
- azotemia, \*246
- cerebral mucormycosis, \*342
- cretinism and diabetes mellitus, \*248
- diabetes in identical twins, 393-395
- emphysema, subcutaneous, \*343
- estriol excretion, S15-S16
- estrogen therapy in retinopathy, \*250
- gastric atony, \*353
- hyperlipemia, S69
- and hypercholesteremia, S69-70
- idiopathic, \*344
- and retroperitoneal fibrosarcoma, \*350
- insulin
  - antagonism, \*443
  - resistance, 122-124
  - and sulfonylureas, \*552
  - and tolbutamide, S37
- Kimmelstiel-Wilson lesions and diabetes, 197-199
- light sensitivity dermatitis, \*346
- lipodystrophic muscular hypertrophy, \*77
- marrow aplasia, fatal, \*353
- mitotic figures in islets of Langerhans, 36-37
- mumps parotitis, \*549
- nephrotic-like syndrome, \*443
- pancreatectomy and pre-existing diabetes, 118-119
- pancreatic islet cell adenoma, \*72
- psychologic factors in diabetes control, \*350
- renal
  - glucosuria, \*547
  - papillary necrosis, \*157, \*246
  - salicylate therapy, long-term, \*344
  - sprue, nontropical, 388-390
  - steatorrhea, diabetic, 390-391
  - therapeutic problems in diabetes, \*248
  - varicella in infancy, \*443

## CATARACTS

- dietary aspects, 377
- in Hiroshima survey, 539
- after hypophyseal stalk section, 468

## CEREBROSPINAL FLUID, and insulin, \*347, \*550-551

## CHILD

- camp programs, \*74, \*249, S75
- corn oil diet effect, \*550
- diabetes onset in identical twins, 395
- dimethylidiguamide therapy, \*73

## galactosemia, \*552

- glucose tolerance curve in normal, 395
- hypoglycemia, 396, 421
- insulin resistance, 122-124
- lipodystrophic muscular hypertrophy, \*77
- liver glycogen disease, \*550
- phenformin and placebo study, \*153
- questionnaire on diabetes, \*247
- tolbutamide response test, S135
- twins, incidence in, 393-395

## CHLOROTHIAZIDE

- and diabetes aggravation, \*75
- and serum lipids, effect on, \*441

## CHLORPROMAZINE, placental transfer, S94

## CHLORPROPAMIDE, \*153-154

- advantages, 94-95
- albumin bound, S19-22
- and alcohol reaction, 40-42
- and blood sugar, 92, 95, \*348, S62-68
- fasting levels, \*246
- carbohydrate metabolism, effect on, \*151
- comparison with
  - azepinamide, S143
  - BH 135, \*439
  - tolazamide, 218
  - tolbutamide, S67
- and diabetes
  - insulin control, \*251
  - maturity onset, \*551
  - severity, S50-54
  - subclinical, S127-129
- and diet, \*160
- failures, \*72, \*249
- secondary, 93
- fatty acids, effect on, S62-68
- and fibrinolysis, \*553
- and glucose release, hepatic, S16-17
- and glucose-6-phosphatase, \*151
- and hypoglycemia, \*552
- insulinogenic potency, \*349, S11-12
- and leucine, 397-400
- and liver, 84, 93-94
- long-term therapy, 91-95, \*252
- and marrow aplasia, \*353
- and nitrogen balance, S50-53
- and perinatal mortality, S99
- and photosensitivity, \*346
- toxicity, 93-94, \*349
- and weight, 94

## CHOLESTEROL

- after acetohexamide therapy, 88
- and atherosclerosis, 65, \*77, 144
- azepinamide effect, S71
- and corn oil diet, \*550
- after exercise, 111-112
- in Hiroshima survey, 539
- MER-29 effect, \*440
- and nicotinic acid, 144
- in obese mice, 212
- after oroti acid, \*76

## CHOROID

- microaneurysm in capillaries, 9
- thickening of basement membranes, 17

## CIRCULATION

- brachial and insulin, 282-283
- and free fatty acid extraction, \*347
- and glucose balance, hepatic, \*346
- insulin, \*245
  - after sulfonylureas, S2
- Issekutz method, 222
- through neuropathic bone lesion, \*76
- pancreatic, insulin-like activity, 504
- peripheral, sulfonylureas effect, S44-48
- portacaval shunt and hepatic glucose, \*270
- portal, insulin effect on, \*73
- retinal
  - after hypophyseal stalk section, 468
  - vascular reactivity, \*74
- splanchnic, \*152, \*155

## CIRRHOSES

- diabetes, association with, \*151-152
- and galactosemia, \*552
- and galactosuria, \*553
- and glucose output, hepatic, 270
- nutritional, \*152

## CLARA BARTON BIRTHPLACE CAMPS, S75

## CLINISTIX TEST, 49-51, \*345

## CLINITEST, copper reduction, 53-55, 92, 111

## COMA, diabetic, \*73

- and hypoglycemia, \*548
- and insulin therapy, 24-25

## CORTICOTROPIN

- and microaneurysms, retinal, 18
- and serum proteins, 105-108

## CORTISOL

- See also Hydrocortisone
- and glucose metabolism, \*550
- transcortin-bound, \*350

## CORTISONE

- acetate after adrenalectomy, 484
- and blood sugar, 211
- and glomerulosclerosis in rabbits, 296
- glucose tolerance test
  - in diagnosis, S132
  - in prediabetics, 50-51, 334, \*350
- and hepatic synthetase, \*78
- histological effects, 402-410
- and hypercholesteremia, \*551
- and hypophosphatemia, 31-34
- and hypophysectomy, 474-475
- and insulin resistance, 32
- liver enzyme, effect on, \*159
- and sulfate, urinary, \*551

## COTTUS QUADRICORNIS L., carbohydrate metabolism, \*154-155

## COTTUS SCORPIUS, pancreatic islet cell study, \*247

## CUSHING'S SYNDROME, \*158, 326

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150



**D**

DBI. *See* Phenethylbiguanide

DEHYDROGENASE activities, 96-99

2-DEOXYGLUCOSE, and muscle sugar transport, 171-177

2-DEOXYGLUCOSE 6-PHOSPHATE, \*78, 171

DEXTROTEST METHOD, \*158

DIABETES MELLITUS

*See also* specific sites  
and abdominal surgery, \*344  
abnormality remissions, \*350-351  
and achylia, \*344  
acid-base balance, 361-363  
and acromegaly, 124  
and Addison's disease, \*78, \*158, \*548  
adrenal glands, \*158  
    hypertrophy and hyperactivity, 326  
age factor in, 46-47, 52, 55, 61-63, 66  
    and azepinamide response, S143  
    in Japan, 535  
alloxan-induced, 18, \*77, \*78  
    adrenal glands, weight gain, 318-320  
    and cold exposure, \*444  
    fatty acid metabolism, 222-223  
    oxidation, impaired, 386  
    and pancreatectomy in dogs, 118  
    and reproductive organs of rats, \*249  
    salicylate, insulin, and chlorpropamide effect on rats, \*151  
    and serum-protein levels in rabbits, 106-107  
    and tolbutamide, S106-111  
    tubular calcification and pyelonephritis, 403  
    and weight gain, 321  
    and wound healing, \*250  
amelioration, spontaneous, and tolbutamide, S106, S114  
angiopathy, 489  
    and hypophysectomy, 474-479  
anorexic therapy, \*74  
Armanni-Ebstein lesion, 296  
and bacteremia, \*347  
basement membrane thickening, 9, 199  
beta-cell activity, \*76  
and blood groups, 329  
brittle disease, \*73  
    and Crystalline Insulin, \*345  
    leucine administration, 397-400  
    protein metabolism deficiency, \*154  
    stable, change to, \*347  
carbohydrate tolerance test, 44-45  
carboxypeptidase concentration, \*75  
and carcinoma of pancreas, 120  
characteristics, 24-28  
chelating agents, \*442  
childhood, \*75  
    and beef-pork insulin resistance, 124  
    and camp programs, \*74, \*249, S75  
    celiac disease, 388  
    dimethylbiguanide therapy, \*73  
    and I.Q. levels, \*342

    and insulin resistance, 122-124  
    management, \*74, \*75, \*548  
    and phenformin, \*153  
    questionnaire response, \*247  
    and chlorothiazide, \*75  
    and chlorpropamide therapy, 40, 91-95, \*246, \*251, S50-54, S127-129, \*551  
    and cholelithiasis, \*252, \*444  
    ciliary process, 9  
    circulatory problems, \*73  
    and cirrhosis, S86, \*151-152  
    classification, \*73  
    complications, \*246  
        atherosclerosis, 422, 425  
        cranial nerve palsy, \*348  
        diarrhea, \*159  
        and gastric secretion, \*344  
        neuropathy, \*153, \*352  
        oculovascular, 472  
        postoperative in gallstones, \*252  
        in pregnancy, 335  
        renal lesions, 291-294, 296-304  
        urogenital, \*552  
        vascular, 470-471  
        and hypophysectomy, 473-478  
congenital, \*347  
control  
    and adrenalectomy, 484-485  
    with desiccated pancreatic extract, 120  
    after hypophysectomy, 480-481  
    and insulin therapy, \*344  
    in Japan, 536-537  
    and neuropathy, \*153  
    and physical activity, 114  
    psychologic factors, \*350  
    and salicylate therapy, \*344  
    and tolbutamide, S74-79  
definition, 335  
detection  
    Drives, 47-48, 81, \*156  
    in older individuals, \*440  
    and tolbutamide, \*350, S97-98, S132-135, S138  
Diabetes Week, 80, 162, 258, 356  
"diabeticity" index, \*442-443  
diagnosis, \*73  
    screening tests, 44-45  
    and tolerance test results, S132-135  
diet, \*74, \*157  
duration  
    and acetohexamide therapy, 87-88  
    and adrenalectomy, 488  
    and albuminuria, S85  
    and azepinamide response, S143  
    and azotemia, S85  
    and estrogen excretion, 517  
    and hypophysectomy, 480-481  
    in Japan, 537-538  
    and neuropathy, \*153-154  
    and retinopathy, \*153  
    by sex and age, S57  
    and tolbutamide response, S37, S85  
emotional factors, \*553  
experimental and human, \*76  
and gallstones, \*252  
gangrene, amputations below knee, \*346

gestational, 227  
and glucosuria, pre-existing, \*547  
glycoprotein metabolism, 2, 18-19  
and growth hormone, 18-19  
    hydrocortisone effect, 177  
haptoglobin types, 331-332  
hematological studies, 18  
and hemochromatosis, \*251  
and heredity, 19, 329-330, 393-395, S138  
and homozygosity, 56-65  
hormonal regulation of glucose, \*153  
hospital responsibility, \*444  
and hypertension, 44-48  
and hyperthyroidism, \*156-157  
and hypophysectomy, 469-470, 470-472  
incidence, 239-240  
    in Britain, 66-69  
    in East Pakistan, \*346  
    in Japan, 44-48  
    Hiroshima, 533-542  
    after mumps, \*549  
    in New England town, \*252  
    after pregnancy, 419  
    by sex and age, 66-69, \*440, 536  
    in South Africa, Durban, \*343  
    in United States, 66-69, \*347  
infection resistance, \*551  
insulin  
    complex, utilization of, 265-266, S34  
    -resistant, \*73, \*348, S34, S35-40  
juvenile, 182  
    glomerulosclerosis, diffuse, \*440  
    and growth hormone production, 18, \*77  
    and hypophyseal stalk section, 465-468  
    and hypophysectomy, 461-462, 463-464, 472  
    and insulin sensitivity, 285, 308  
    in Japan, 540  
    and nuclear enlargement in islets of Langerhans, 38  
    and phenformin therapy, \*153  
    and phenmetrazine hydrochloride therapy, \*74  
ketosis, \*157  
lipoatrophic, \*77, \*344  
manifestations, early, S72  
maternal  
    and carbon dioxide pressure, \*347  
    and menarchial age, 288  
    and subcutaneous fat necrosis, \*351  
maturity onset  
    and acetohexamide, \*551  
    and azepinamide, S142-145, S146  
    combined oral hypoglycemic therapy, \*249  
    and tolbutamide, S70, \*551  
metahypophyseal, \*547  
mild, and tolbutamide, S123-126  
and mitochondrial reactions, \*343, \*546  
and mitosis in islands of Langerhans, 38  
and mucormycosis, \*155  
and mucoviscidosis, \*75

**DIABETES: VOLUME II PAGE NUMBERS BY ISSUE**

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

after myocardial infarction, \*251  
and myotonic dystrophy, \*552  
necrosis in feet, \*76  
and nephropathy, \*152  
and obesity, 46-47, 70, 109  
acetoexamide therapy, 87, 89  
diethylpropion therapy, \*549  
and insulin antagonist, 72  
sex factor, \*151  
and pancreatic cystic fibrosis, \*73  
patient instruction, 132-137  
and phenformin therapy, 283  
and physical training, 109-117  
and polyneuropathy, \*549  
in pregnancy, \*152  
and fetal loss, \*72, 228  
and tolbutamide  
therapy, S97-98  
transfer, S93-96  
protein synthesis, effect on, 145, \*154  
pyruvate level in blood, 285  
radiation effect in Hiroshima, 535  
renal  
glomerular crescents in lesions, 303-304  
papillary necrosis, \*157  
research tools, use of, \*439  
retinal vessels  
changes in rats, \*156  
increase in number, 9  
and oxygen inhalation, \*74  
and seminal deficiency, \*349  
severity  
and leucine incorporation, \*348  
and serum protein-bound iodine level, 193  
and sulfonylureas, S50-53  
sex factor, 46, \*151  
in East Pakistan, \*346  
and Simmond's disease, 18  
and socio-economic levels, 46-47  
special vocabulary, 135-136  
and sprue, nontropical, 388-391, 436-437  
stable  
insulin secretion, S66  
and phenethylbiguanide, \*551  
statistics on, 66-69  
and cirrhosis, \*151  
and steatorrhea, 388-391, 436-437, \*439  
subclinical and chlorpropamide, S127-129  
survey  
in Birmingham, England, \*440  
in Halstead, England, \*441  
in Hiroshima, Japan, 533-542  
syndrome, 200  
teaching in medical schools, 43, 48  
therapeutic problems, \*248  
and thiazide drugs, \*251  
thiol substances and diabetogens, \*347  
and trace metals, \*248  
treatment, \*72, \*77, \*248, 336-338  
check list, 117  
chlorpropamide and insulin, \*251  
conservative and gangrene, \*547  
exercise, diet, and insulin, 109

in Japan, 536-537  
medical and surgical, \*73  
with oral hypoglycemic agents, *see* Supplement, \*72, 83-88, 91-95, \*153-154, \*155-156, \*249, \*553  
of prediabetes, \*252  
with sulfonylureas, S80-84  
and tuberculosis in Japan, 539  
in twins, 393-395  
untreated  
and diarrhea, \*159  
insulin-like activity, \*158, 179  
and vas deferens calcification, \*152  
DIABETES WEEK, 80, 162, 258, 356, 455  
DIARRHEA  
and neuropathy, \*252  
nocturnal, \*159  
DIET  
adenine supplement, \*76  
and atherosclerosis, \*77, 221, 338  
beta-glucuronidase dosage, 65  
caloric intake, \*74, 113-114, 336, \*350  
and islet tissue, \*551  
and physical fitness programs, 111  
and tolbutamide, S124-125  
and tolerance tests, S182  
carbohydrate intake, \*154  
and hyperglycemia, 510  
and cataracts, 377  
and cholesterol level, 144  
and cirrhosis, \*152  
corn oil, \*550  
for diabetic children, \*75  
and "diabetic" index, \*442-443  
and glucose  
-galactose, \*246  
and nitrogen values, S50-51  
uptake, \*246  
and glucostatic theory, \*444  
ground fox breeder ration, S115-116  
in Japan, 536  
and mellituria, \*246  
polyunsaturated vegetable fat in, 339  
in pregnancy, diabetic, \*152  
protein  
high, 338  
and hyperinsulinism, \*75  
low, \*250  
restriction effect, \*74  
saltless, 337-338  
soft, S116  
starvation, 336  
and glycogenolysis, \*353  
and hexose phosphates, \*76  
and steroid lesions, 402-405  
in sulfonylureas therapy, S82  
phenformin, S90  
tolbutamide, S77, S90, S94  
synthetic and glucose tolerance, \*443  
unrestricted and chlorpropamide, \*160  
DIMETHYLDIGUANIDE, \*73  
*See also* Metformin

## E

EAST PAKISTAN, MEDICAL RESEARCH CENTRE, diabetes incidence, \*346  
ELECTROPHORESIS  
Durrum method, 272  
in Hiroshima survey, 539-540  
insulin  
antagonist mobility, 308-309  
-binding capacity of plasma, 165  
complexes, dissociation of, 263  
derivatives, \*553  
free and bound, S26-28  
protein and enzyme peaks, 273  
serum patterns, 105  
sulfonylureas, S19-21  
EMIOCYTOSIS, 510-511  
ENGLAND  
diabetes survey  
in Birmingham, \*440  
in Halstead, \*441  
ENZYMES  
acetate determination, \*76  
activity  
in acinar tissue, S5  
and incubation, 96-97  
and cortisone, \*159  
and galactose metabolism, \*157  
galactosemia, \*552  
and glycogen storage disease, \*75, \*441, \*547, \*550  
insulin degradation, 271-278  
and toxicity, \*442  
EPINEPHRINE  
and adrenalectomy, \*159  
carbon dioxide liberation, \*247  
and cortisol, \*550  
and fatty acids, 223-224, \*252  
-mobilizing activities, \*343  
and glucagon  
and hypoglycemia, neonatal, \*444  
and glucose, hepatic, \*549  
glycogenolysis, effect on, \*158  
hexose phosphates concentrations, \*76  
and hyperglycemia, \*250  
and hypoglycemia in children, \*72  
and insulin, 396, 421  
antagonism, 225  
sensitivity, \*343-344  
and lipolysis, \*246  
and methandienone, \*550  
in urine after adrenalectomy, \*159  
ERYTHROCYTES  
antibodies  
activity, 413  
and heat labile factor, 188  
glucose  
metabolism, \*548  
transfer, \*349, \*350  
glucose-6-phosphate, \*553  
dehydrogenase activity, \*442  
pentose phosphate pathway, \*78

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

## ESTROGENS

- excretion during pregnancy, \*351
- production, 517
- and retinopathy, \*250

## ETHANOL

- See also Ethyl alcohol
- and galactose
- elimination, \*553
- metabolism, \*157

## ETHYL ALCOHOL

- See also Ethanol
- and chlorpropamide, sensitivity to, 40-42
- and galactose metabolism, \*157
- and tolbutamide, \*442

## EYE

- See also Choroid, Retina, Retinopathy,
- cataracts, 377
- hemorrhages, 463
- myotonic dystrophy effect, \*552
- optic nerve glioma, 127

## F

### FAMILIAL TENDENCY, \*76

- See also Genes, Heredity
- data on diabetes, request for, 71
- and diabetes onset prognosis, 63-64
- and haptoglobin types, 331-332
- in Hiroshima, Japan, 534-535
- and hypertension, \*251
- and hyperthyroidism, \*156-157
- and hypoglycemia, 397
- and leucine sensitivity, \*344-345
- and menarchial age, 288
- mucoviscidosis, \*75
- pancreatic cystic fibrosis, \*73, \*343
- and perinatal mortality, \*76, \*156
- and prediabetes, \*72, 334
- and renal lesions, 199
- and tolerance tests, S133-135
- in young diabetics, S123, S126

### FATS. See Lipids

### FATTY ACIDS

- in adrenal cortex, 319
- esterification, \*442
- free, removal and mobilization, \*548-549
- after glucose and epinephrine, \*252
- hepatic uptake, 222-225
- insulin response, 366
- metabolism, S44
- myocardial, \*152
- oxidation by heart muscle, \*248
- rat epididymal fat pad, release from, \*343
- removal, \*347
- from plasma, \*347
- and serum, anti-insulin, \*553
- sulfonylureas effect, S61-68

### FETUS

- abnormalities, \*72, S98, S99, 514
- age and weight, \*72, \*152

- carbohydrate metabolism in liver, \*248
- insulin-degrading factors, 420
- islets of Langerhans development, \*157
- loss, \*72, 228
- and acidosis, \*346
- and estrogens, 516
- macrosomia, \*444
- weight and mortality, 321

### FIBRINOLYSIN, and arterial thrombi, \*250

### FLORINEF. See 9-alpha-fluorohydrocortisone

### FOLIN-MALMROS METHOD, S104

### FOLIN-WU METHOD, 204-208

### FRUCTOSE 1:6-DIPHOSPHATE, \*76

### FRUCTOSE 6-PHOSPHATE, \*76, \*78

## G

### GALACTOSE

- and hypoglycemia, neonatal, \*444
- metabolism, \*157
- uptake and insulin, \*155, 422-423

### GALACTOSEMIA, \*157

- congenital, \*159-160, \*552

### GASTRECTOMY, and circulatory collapse, \*152

### GASTRIC SECRETION

- basal and post-histamine, \*344
- and glucagon, \*73, \*75
- insulin response, \*547

### GASTROINTESTINAL TRACT

- azepinamide effect, S144
- and diarrhea, diabetic, \*159
- and phenformin tolerance, \*153, \*349

### GENES

- See also Familial tendency, Heredity
- and galactosemia, \*160, \*552
- homozygosity, 56
- and hypothalamus function, 209
- and menarchial age, 288-289
- mucoviscidosis and diabetes, \*75
- recessive diabetes permissive, 56
- in twins, identical, 393-395

### GLOMERULI

- nodular lesions and insulin, 314
- steroid treatment, effect of, 405-409

### GLOMERULONEPHRITIS, \*246

- and glomerular crescents, 303-304

### GLOMERULOSCLEROSIS, 9, 47, 197-200

- in alloxanized rabbits, 107
- and crescent formations, 303
- forms, 296-304, \*440
- renal biopsies, \*549
- steroid-induced, 405-410
- and vascular lesions, 302-303

## GLUCAGON

- and capillary blood sugar, \*153
- and gastric secretion, \*73, \*75
- and glucose, hepatic, \*549
- and glycogen, hepatic, \*77-78, \*248
- and glycogen storage disease, \*444
- and hepatomegaly, \*550
- high specific activity preparation, \*347
- and histamine dosage, \*73
- and hyperglycemia, \*158
- in infants, \*153
- in hyperinsulinism therapy, \*75
- and hypoglycemia, neonatal, \*444
- and insulin sensitivity, \*343-344
- in insulinoma detection, \*250
- and methandienone, \*550
- after phenformin therapy, \*72
- production site, 373

## GLUCOCORTICOIDS

- and glycogen synthesis, hepatic, \*77-78
- metabolism, effect on, \*158
- and muscle insulin response, 175-177

## GLUCOSAMINE 6-PHOSPHATE, \*78

## GLUCOSE

- See also Blood sugar, Glycosuria, Hyperglycemia
- and adrenal steroids, 31-34
- in adrenalectomized rats, \*159
- binding by insulin, \*342
- and blood insulin-like activity, \*247
- carbon dioxide
- conversion, 368
- liberation, \*247, 319
- and erythrocyte membrane, \*349-350
- and fibrinolysis, \*553
- and free fatty acids, 224
- gastrectomized patients, effect on, \*152
- and glutathione stability, \*345
- hormonal regulation of, \*153, 171-177
- and hyperglycemia, \*250
- and hyperinsulinism, \*74
- Increment Index, S127-129
- and insulin
- free and bound, 70
- after phenformin, \*72
- insulinogenic potency, \*349, S11-12
- labeled
- in islet tissue of *Cottus Quadricornus* L., \*154
- in pineal gland of goats, \*249
- in mathematical model, \*159
- metabolism
- in diabetic rats, \*78
- hexose monophosphate pathway, S2
- in ketosis, bovine, \*351
- myocardial, \*152
- and portacaval shunts, \*73
- and sulfonylureas, 507
- and methoxypropyl-sulfonyl-urea, S16-17
- and muscle protein synthesis, 145
- oxidation
- in erythrocytes, \*78
- insulin, effect of, 386
- and overactive thyroid, \*342

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360  
Volume II Supplement, 1-150

September-October, 361-460  
November-December, 461-562

# SUBJECT INDEX 1962

- phlorizin effect, \*249  
 phosphorylation, 31, \*442  
 production, 366-368  
 radioactive, \*153  
 retention and insulin, 270  
 from retroperitoneal fibrosarcoma, \*353  
 and salt retention, \*441  
 skin-surface test, \*76  
   and blood test, 49-51, 202-203  
   in prediabetics, 50-51  
   and urine test, 49-51  
 splanchnic blood flow and oxygen consumption, \*155  
 tolerance tests, \*245, 534  
   adrenal steroids effect, 31-32  
   chlorpropamide effect, S62  
   diabetic index, \*442-443, S104-114  
   in diagnosis, S132  
   glucose oxidase paper method, \*440, \*441  
   infants of diabetic mothers, \*245  
   long-term follow-up, \*440  
   and methandienone, \*549  
   after myocardial infarction, \*251  
   in old people, \*154  
   and pancreatic cancer, \*246, \*439  
   physiologic significance, \*548  
   and prediabetes, 334  
   in pregnant  
     diabetics, \*72, 227  
     nondiabetics, \*158  
   reproducibility, \*245  
   in siblings of diabetics, 395  
   after surgery on sphincter of Oddi, \*248  
   and thiazide drugs, \*251  
   tolbutamide effect, S62, S109-114, S123-126  
 transfer  
   across cell membrane, \*548, \*549  
   temperature and pH effect, \*349  
   and transfer inhibitors, \*349-350  
 uptake  
   in aortic tissue, after insulin, 422  
   in epididymal adipose tissue, 101-103, 179, 187, \*246, S138  
   Fick Principle, 281  
   and glyceride-glycerol synthesis, \*246  
   and lactose, \*246  
   in liver, after insulin, 366-368  
   after L-leucine, \*440  
   by myocardium, \*547  
   after radiation, \*151  
   uridine diphosphate, \*77-78  
   utilization and cystamines, \*548
- GLUCOSE - 6 - PHOSPHATASE, \*151, \*442**  
 and glycogen storage disease, \*441, \*444, \*547, \*550  
 liver, increase in diabetic, 365  
 sulfonyleureas effect, S8  
 and tolbutamide, S116-120
- GLUCOSE-6-PHOSPHATE, \*76, \*78, \*553**  
 and refeeding, \*159
- GLUCOSE-6-PHOSPHATE DEHYDROGENASE, \*78**  
 beta and acinar cells, activity in, 98-99  
 and hemolytic anemia, \*345  
 in Mulia population (Netherlands New Guinea), \*442
- GLUTAMIC ACID, \*249**
- GLUTATHIONE**  
 and acetyl-phenyl-hydrazine, \*345  
 oxidized, 272, \*345  
 reductase, and disulfide bonds, 272-278
- GLUTATHIONE-INSULIN TRANSHYDROGENASE. See Transhydrogenase**
- GLYCOCORTICIDS, and serum proteins, 105-108**
- GLYCOGEN**  
 beta cell, deposition in, 427-431  
 and glucagon response, \*158  
 and glucose phosphorylation, \*547  
 hepatic synthesis, \*77-78  
 metabolism  
   and endocrine regulation, \*78  
   in skin, \*151  
   and phenformin, 285  
 storage disease, \*75, \*441, \*547, \*550
- GLYCOGENOLYSIS, mathematical model, \*159**
- GLYCOPROTEIN**  
 in basement membrane, 294  
 level in plasma, 18-19
- GLYCOSURIA**  
*See also* Blood sugar, Glucose, Hyperglycemia  
 and chloramphenicol therapy, \*345  
 in diabetes detection, \*156  
 and exercise, \*74  
 Fehling's method test, 49-50  
 and growth hormone, \*346  
 and hypertension, 47  
 incidence  
   in Birmingham, England, \*440  
   in Halstead, England, \*441  
 insulin  
   resistance, 125  
   after nicotinic acid, 144  
   and phenformin, S51-54  
   in pregnancy, 227  
   under stress, 213  
   and tolazamide, 216
- GOITER**  
 hyperendemic and nervous system defects, \*442  
 toxicity and diabetes, \*342
- GOLDTHIOGLUCOSE, and massive obesity, 209-212**
- GOLGI APPARATUS**  
 endoplasmic reticulum, 427  
 and microinvaginations, 380-382  
 vesicle distention, 428-429
- GROWTH HORMONE**  
 dog islets, effect on, 426-433  
 and fatty acid mobilizing activities, \*343  
 and glucose transport, 174-177  
 and hyperglycemia, \*551  
 and hypophysectomy, 461  
 and lipid metabolism, \*346  
 and lipolysis, \*246  
 and plasma amino-acid level in alligator, \*247  
 and protein  
   -bound carbohydrate elevation, 18-19  
   synthesis, \*249  
 sensitivity, 212-213
- ## H
- HAGEDORN JENSEN METHOD, 31, 44, 202, 210, S138**
- HEART**  
*See also* Myocardium  
 contractility and sugar permeability, \*78  
 glucose uptake, \*547  
 muscle  
   fatty acid oxidation, \*248
- HEART DISEASE**  
 arteriosclerotic  
   and serum lipids, \*252  
 coronary, \*151  
 amyloclastic action of saliva, \*351  
 in Hiroshima survey, 538  
 and serum lipids, \*252
- HEMOCHROMATOSIS**  
 among Bantu diabetics, \*251  
 in Hiroshima survey, 538
- HEMORRHAGE**  
 in glomeruli, steroid-treated, 408-409  
 and hypophysectomy, 462, 469, 471  
 in plexiform layers of retina, 14  
 resorption after adrenalectomy, 487-488  
 in retinopathy, 466, 473  
   and hypophyseal stalk section, 467-468  
 vitreous, 484-485
- HEREDITY**  
*See also* Familial tendency, Genes and blood  
 groups, 329-330  
 vessel defects, 19  
 and cystic fibrosis, S136  
 of diabetes, 393-395  
 and prediabetes, S138  
 recessive gene, permissive, 56  
 galactosemia, \*159-160, \*552  
 glucose tolerance, pathologic, \*352  
 and leucine sensitivity, \*344-345  
 obesity and hyperglycemia, 212-213  
 single genetic locus, 56-65

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
 March-April, 83-164

May-June, 165-260  
 July-August, 261-360

September-October, 361-460  
 November-December, 461-562

Volume II Supplement, 1-150



# SUBJECT INDEX 1962

**HEXOSE MONOPHOSPHATE SHUNT**  
in beta cells, 98-99  
and glucose metabolism, 99

**HEXOSES**, and overactive thyroid, \*342

## HORMONES

See also specific substances

adrenal, \*343-344

and estrogen administration, 514

and free fatty acid metabolism, 222-226

and glucose

production, \*153

uptake, \*352

and hypophysectomy, 474-475

insulin antagonists, \*443

mammotropic and somatotrophic, \*250

and metabolic changes, 424

and sulfate, urinary, \*551

testicular fat, effect on, \*158

therapy during pregnancy, \*351

## HYALINE MATERIAL

in arterioles, 9-11

necrobiotic changes in retina, \*351

in renal blood vessels, 299-300

**HYALINE MEMBRANE DISEASE**, \*249

**HYDROCHLORIC ACID**, secretion-reducing factor, \*344

## HYDROCORTISONE

and adrenalectomy, 486-489

and blood sugar, 174

and glucagon response, \*248

and hyperglycemia, 31-34

and muscle insulin response, 175-177

and plasma amino-acid level in alligator, \*247

## HYDROGEN ION CONCENTRATION

analysis, end-group, 273-274

and glucose transfer, \*349

glycogen synthesis, effect on, 367-368

## HYPERCHOLESTEREMIA

and cortisone, \*551

sulfonylureas effect, S69-72

## HYPERGLYCEMIA

after alloxanization, 106-107

and beta cell release, 511-512

and 2, 2'-bipyridine, \*441-442

and blood pressure rise, \*348

and cortisone, \*551

in diabetic mothers, \*245

after epinephrine, \*250

after exercise, 109

after glucagon, \*73, \*158

goldthioglucose-induced, 209-213

and growth hormone, \*346, \*551

treatment, 432-434

and hepatic glucose, \*73

and hypertension, renal, 47

in infants, \*153

Cushingoid appearance, 326

water content, 324

insulin production, free and bound, 70

maternal and fetal, 321

after myocardial infarction, \*251

after nicotinic acid, 144

under stress, 213

and tolazamide, 216

and toxemia of pregnancy, 227

## HYPERINSULINISM

and islet cell tumors, \*75

and islets of Langerhans, \*153, \*248

and neuropsychiatric problems, \*72-73

symptoms, \*75

## HYPERLIPEMIA

glomerular, 410

after physical training, 114-115

sulfonylureas effect, S69-72

## HYPERTENSION

and basement membrane thickening, 9

in diabetes detection, 44-48

and hemodynamic lesions, 304

and proteinuria, 538

## HYPERTHYROIDISM

and carbohydrate oxidation, \*442

familial tendency, \*156

and monosaccharide uptake, 423-424

and radio-iodine therapy, \*342

## HYPERTRIGLYCERIDEMIA, S57

## HYPOGLYCEMIA

after acetohexamide therapy, 84-87

and adrenalectomy, 487

from adrenocortical insufficiency, 171

azepinamide effect, S144

and brain syndrome, \*72-73

in children, 396, 421

insulin-induced, \*72

and chlorpropamide, 93, \*160

and leucine, 397-401

as conditioned reflex, \*342

desoxyribonucleic acid, \*350

and gastric secretion, \*352

glucose

-oxidase method in emergency, \*351

radioactive, \*549

after hypophysectomy, 463, 481

and indole-3-acetic acid, \*343

in infants, S136-137, \*549

and varicella, \*443

and insulin, \*547

antibodies, 519-522

derivatives, \*553

and intrathoracic mass, \*439

after leucine, \*250

and leukemia, \*247-248

and methandienone, \*549

neonatal, \*444

and phenformin, \*160, 282-285

and pituitary insufficiency, 492

and retroperitoneal tumor, \*548

and spinal cord lesions in rats, \*158-159

spontaneous, \*248, 337, \*353

after tolbutamide, \*250, S29, 507

islet cells, effect on, S125

and leucine, \*547

treatment, \*344

## HYPOGLYCIN A

testicular fat, effect on, \*158

## HYPOPHYSEAL STALK SECTION

See also Hypophysectomy

and angiopathy, diabetic, 474

and retinopathy, 465-468, 470, 491-494

## HYPOPHYSECTOMY

and adrenal weight, 324

after adrenalectomy, 487-488

and amino acid incorporation, \*249

and diabetes insipidus, 474-475

and gastric secretion, \*344

and glucagon reaction in baboon, \*158

and hyperglycemia, 322-324

and water retention, 324

and weight of rat offspring, 323

and hypoglycemia, \*342

and hypopituitarism, 175-176

and insulin, \*155, 262

and islet weight studies, S116-120

and oculo-vascular sequelae, 472

patient selection, 463, 466, 471, 473

and retinopathy, 461-462, 463-464, 491-494

beneficial changes, 467, 469

transantropenoidal, 479, 480

for vascular diseases, 470-471

**HYPOTENSION**, postural, \*352

## I

## INDEX

diabetic, S104-114

Increment, S128

## INDOLE-3-ACETIC ACID

hypoglycemic activity, \*349

insulinogenic potency, S12

## INFANTS

blood sugar levels, \*444

congenital defects and sulfonylureas, S98, S99, S144

of diabetic mothers

blood sugar, \*153

and carbon dioxide pressure, \*347

early vs. late feeding, \*249

insulin secretion, \*245

mortality, \*158, S99-100, \*549

subcutaneous fat necrosis, \*351

erythroblastotic, and enlarged nuclei

in islets of Langerhans, 36

galactosemia, \*552

and hypoglycemia, fatal, \*443

islet cell adenomas, S136

size and estrogen, 517

and tolbutamide

response test, S135

transfer, S94-96

## INSULIN

and oleic acid, \*549

acetohexamide effect, 89

and acid metabolism, \*546

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-164

May-June, 165-260

July-August, 261-360

September-October, 361-460

November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

- activity, 369, \*442  
 action-like, 179, \*249  
 and adrenal steroids, 31-34, 165-169, \*352  
 in fibrosarcoma, \*353  
 after tolbutamide, S8, 504-508  
 after adrenalectomy, 484  
 allergy, \*348  
 and amino acid uptake, \*342  
 antiserum, \*77, \*160  
 neutralization, 414-418  
 preparations, 412-413  
 aortic wall, effect on, 422-425  
 assays, 69-70, \*77  
 Berson and Yalow method, \*157  
 beta cells, 101-104  
 bound and free, \*245  
 epididymal fat pad method, 101, 172, 179, 184-185, \*245, 506  
 manometric, \*245  
 standard curve analysis, 413-414  
 beef-pork, 124-125  
 -binding  
 of globulin, albumin, fibrin, antihuman, 309, 317  
 in glomerulosclerosis, 308-317  
 and blood pressure, \*348, 396, 421  
 and carbohydrate metabolism, \*245  
 in cerebrospinal fluid, \*347, \*550-551  
 characteristics, \*344, \*345  
 and chlorpropamide, \*251  
 circulating  
 carrier protein bound, 417  
 immunological studies, \*77  
 -coated bentonite particles, 520  
 phagocytosis, 522-523  
 coma, 24-25  
 and cortisol, \*550  
 and mouse mammary tissue, \*250  
 Crystalline, 101, 125, \*245, 262, 265, 309, 319  
 and brittle disease, \*345  
 and serum antibodies, \*151  
 tolbutamide effect, S1, S26-33  
 Zinc and hypoglycemia, 23-24  
 and cyclotolheptamide, S12  
 depot, \*74  
 derivatives, \*553  
 vs. diet control, 336-337  
 dosage  
 and binding capacity, 528-530  
 and brittle disease, \*347  
 and coronary atherosclerosis, \*77  
 after exercise, 109  
 and phenethylbiguanide, \*348  
 and serum phosphorus level, 29-32  
 small and large, comparison, 23-30  
 and steroid therapy, 166-168  
 and epinephrine  
 antagonism, 225  
 excretion, \*159  
 free and complex, 262-266  
 and free fatty acids, 224  
 and galactose uptake, \*155, 423  
 and gamma globulin excess, 107  
 and gastric secretions, \*75  
 and glucose, S14  
 distribution, \*549  
 after fasting, 281  
 metabolism, 26-29  
 output, 270  
 after phenformin, \*72  
 transfer, \*548  
 uptake, \*346, S14  
 in adipose tissue, \*352  
 by myocardium, \*547  
 and glucose-6-phosphatase, \*151  
 and glycogen synthesis, \*77-78  
 in guinea pigs, 104  
 and heat labile factor complexes, 188  
 hexose phosphates, effect on, \*76  
 and hexoses incorporation, \*78  
 history, 495-503  
 human  
 and antisera from guinea pigs, \*160  
 preparation and purification, \*151  
 and hyperadrenocorticism, 171  
 and hyperthyroidism, 124, \*342  
 and hypoglycemia, \*444  
 in hypophysectomized dogs, \*342  
 hypophosphatemic effect, \*547  
 immunization  
 by Morse method, 527  
 and tolbutamide, S28-29  
 Lente types, \*160, \*349  
 and leucine, \*552  
 and liver glycogen disease, \*550  
 and liver synthetase, \*78  
 and metformin, \*345  
 and methandienone, \*550  
 mitochondria, effect on, \*343, \*546  
 in pancreatic beta cells, 103  
 peptides, chemical synthesis, \*441  
 and phenethylbiguanide, \*551  
 and phlorizin, \*550  
 and phosphate bond production, \*343  
 and potassium, \*442  
 transfer in rat liver, \*156  
 Protamine Zinc  
 absorption from subcutaneous tissue, \*245  
 lipid, effect on, \*158  
 and wound healing, \*250  
 and protein synthesis, 144-147, \*154  
 in prediabetes, 145  
 radio-active, solubility of, 273-274  
 release mechanism, 510-511  
 reoxidation, 278  
 and reproductive organs, \*249  
 requirement, \*74  
 and dimethyldiguanide, \*73  
 after hypophyseal stalk section, 465-468  
 after hypophysectomy, 462, 471, 474, 480  
 and hypothyroidism, \*248  
 and metabolism, S82-83  
 and pancreatotomy, 119-120  
 and phenformin, long-acting, \*153  
 and pituitary insufficiency, 492  
 and prednisone, 125  
 and tolazamide, 220  
 resistance, \*73, \*76, \*440, \*442, \*443  
 in albumin fractions, \*76  
 circulating antibodies, \*348  
 in diabetic child, 122-125  
 to glucagon excess, 209  
 and ketoacidosis, 23, 80  
 and other disease states, \*343  
 in pregnancy, 227  
 and steroid therapy, 168  
 and sulfonylureas, \*552  
 tissue and serum, S41  
 response  
 in acromegaly, 171  
 after growth hormone, 176-177  
 and tolbutamide therapy, S35-40  
 and salicylate binding, \*350  
 secretion  
 in children, S136-137  
 into pancreatic venous blood, \*349  
 sensitivity, 282  
 in children, \*72  
 and deoxycorticosterone acetate, \*343-344  
 after epinephrine, \*247  
 in serum  
 free and protein-bound, 69  
 species specificity, \*443  
 stimulation  
 in phosphate medium, 368  
 and sulfonylureas, S12  
 storage form, 510  
 and thiazide therapy, \*251  
 thyroxine degradation, correction of, 192  
 and tolbutamide, \*546  
 comparison of effects, S26-33  
 regulation by, S34-35  
 tolerance  
 after adrenal steroids, 31-32  
 transhydrogenase reduction, 271-278  
 withholding effects on liver, 366  
 and xylose uptake, 422  
 and zinc association, \*248, \*345, \*349
- INTERNATIONAL DIABETES FEDERATION  
 Fifth Congress, 258, 356  
 Fourth Congress  
 erratum, 387  
 papers presented, 138-143, 228-235
- IODINE, serum protein bound, 193-195
- ISCHEMIA  
 neuropathy, \*76  
 vibratory perception changes, \*350-351
- ISLETS OF LANGERHANS  
 amino acids distribution, \*154-155  
 cells  
 alpha, elimination of, 97-98, 102-103  
 beta  
 degranulation, 212  
 hyperplasia, S129  
 and insulin, 509-513  
 and dehydrogenase activity, 98-99  
 fetal development, \*157  
 glucagon content  
 staining technics, 371-372  
 glucose  
 carbon incorporation, \*249  
 metabolism, \*154-155

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
 March-April, 83-164

May-June, 165-260  
 July-August, 261-360

September-October, 361-460  
 November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

hyperplasia, \*153, \*248  
in animals, 35, \*74  
insulin concentrations in, 102-103  
microchemical studies, 96-100  
mitotic figures, 37-38  
nuclei, enlarged, 36  
pregnancy effect, 420  
tumors, \*156

ISSEKUTZ METHOD, 222

## J

### JAPAN

incidence of diabetes, 44-48  
in Hiroshima, 533-542

JOLLIFFE, Norman, 147-149

JOSLIN, Elliott Proctor, 242-244

JOSLIN CLINIC, \*76, 287, S69, S74

## K

### KETOACIDOSIS

See also Acidosis, diabetic  
and bicarbonate conversion, 29  
and I.C-14-acetate, \*157  
and insulin, Lente types, \*160  
and phenformin therapy, \*160  
in tropical regions, \*346

### KETONE BODIES

blood levels, \*157  
physiological role, \*75  
production  
and acetate, \*157  
and insulin, 29-30

### KETONEMIA

after fasting, \*547  
and insulin  
dosages, 29  
hypoglycemia, \*439

### KETOSIS, \*76

and acetate, \*157  
and cerebral damage, \*74  
and chlorpropamide therapy, 93  
endocrine gland role, \*439  
and exudative cellular response, \*551  
fatalities, \*73-74  
and glomerulosclerosis, diffuse, \*440  
insulin-like activity, 179  
in Japan, 541  
and lipogenesis, \*351  
in pancreatectomized animals, \*247  
and plasma fatty acids, 223

### KIDNEYS

blood vessels  
infarction, 304-305  
glomeruli  
basement membrane thickening, 291-294  
lesions in dogs, 150

glomerulosclerotic, \*440, 486  
and insulin-binding, 310-317  
hypophysectomy effect, 470, 473, 477, 479  
impairment and surgery risk, 492  
insulin uptake, S39  
lesions  
fluorescent insulin staining, 375  
steroid-induced, 403-410  
papillary necrosis, \*157, \*246  
pyelonephritis, chronic, 466  
substrates metabolism, \*550

### KIMMELSTIEL-WILSON SYNDROME,

9, 47, \*440  
in animals, diabetic and nondiabetic, 107-108, 150  
basement membrane thickening, 294  
and diabetes mellitus syndrome, 197-200

## L

### LACTIC ACID

myocardial metabolism, \*152  
production, \*249

### LEUCINE

and chlorpropamide, 397-400  
and hypoglycemia, \*547, \*552  
liver incorporation, \*348  
sensitivity, \*250  
in children, S136-137  
familial tendency, \*344-345

### LEUKOCYTES

abnormality in galactosemia, \*160  
and glycogen-storage disease, \*75  
metabolic defect, \*159-160

### LIPIDS

in adrenal cortex, 17, 319  
beta-glucuronidase effect, 65  
chlorothiazide effect, \*441  
and corn oil diet, \*550  
in cortisone preparations, 296  
in diet, diabetic, \*350  
and glucose uptake, \*246, 367  
hormones, effect of, \*158  
metabolism, \*74, S57  
endocrine influences, S61-68  
and hypophysectomy, 471  
orotic acid effect on liver, \*76  
osmium tetroxide stain, 378  
and peptide in urine, \*246  
pyruvate conversion, \*248  
in retinal  
capillaries, 126  
exudates, 12-14  
and serum, anti-insulin, \*553  
tolerance, S56-60  
transport and lipoprotein interconversions, \*154

### LIPODYSTROPHIC MUSCULAR HYPERTROPHY, \*77

### LIPOPROTEINS

and retinal and renal lesions, 107-108  
ultracentrifuge study, \*154

### LIVER

amino acid incorporation, 145, \*249  
biochemical abnormalities, \*441  
and blood insulin-like activity, \*247  
chlorpropamide effect, 93-94  
cirrhosis and diabetes, \*151  
enzyme  
insulin-degrading, 272-278  
synthesis, \*159  
extract principle, \*443  
free fatty acid uptake, 222-223  
function tests  
after tolbutamide, S77, S87  
glucose  
and insulin, 270, \*346, 366-368, \*549  
load disposal, S14  
mathematical model, \*159  
output and renal excretion, S45  
and phlorizin, \*249  
uptake, \*73  
glucose-6-phosphatase activity, \*151  
glycogen  
content, 87, \*158, S17  
depletion, \*159, \*342  
disease, \*441, \*547, \*550, \*553  
insulin uptake, \*157, S39  
ionic patterns, 363-364  
lipids, \*553  
and carbohydrates, \*250  
lipogenic inhibitory mechanisms, \*250  
metabolism and insulin, 366  
mitochondrial reactions, \*343, \*546  
and mitotic figures, 35-38  
orotic acid effect, \*76  
phosphogluconate oxidation pathway, \*441  
and phosphorylase activity, \*75, \*159  
potassium content and insulin, \*156  
in pregnant diabetics, \*248  
salicylates administration effect, \*77  
sulfonyleureas effect, 507  
and tolbutamide, \*349  
toxicity studies, 93  
and triglycerides, \*345-346

## M

MARION COUNTY GENERAL HOSPITAL, DIABETES CLINIC, 87

MARYLAND, UNIVERSITY OF, HOSPITAL, 23-30

MASSACHUSETTS GENERAL HOSPITAL  
diabetes patients, care of, \*444

MAYO CLINIC, \*74-75

MELLITURIA, \*246

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-164

May-June, 165-260

July-August, 261-360

September-October, 361-460

November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

## METABOLISM

acid, in rat adipose tissue, \*546  
carbohydrate, \*151  
  in aortic tissue, 422-425  
  carbon dioxide requirement, 367-369  
  endocrine influences, S61-68  
  and heart disease, \*351  
  in infants, \*153  
  insulin effect, \*245  
  and thiazide therapy, \*251  
ethanol  
  tolbutamide effect, \*442  
fatty acids, \*74, 222  
d-galactose, \*157  
glucagon and adrenalectomy, \*248  
glucose, \*249  
  cortisol effect, \*550  
  in diabetic rats, \*78  
  Embden-Meyerhof pathway, \*246, 365  
  and hexokinase level, \*548  
  hexose monophosphate shunt, 99  
  and insulin, 99, \*353  
  and ketosis, \*351  
  and phenformin therapy, 282-286  
  in pregnancy, \*158, 227  
glutamate, \*159  
glycogen in skin, \*151  
glycoprotein in diabetics, 18-19  
hypophysectomy effect, 470-472  
and insulin  
  free and complex, S34-35  
  L(+)-lactate, effect on, \*353  
lipids, 557  
  endocrine influences, S61-68  
  mannose in diabetic rats, \*78  
  myocardial, \*152  
  otic acid effect, \*76  
  oxidative phosphorylation, \*343, \*546  
  phosphate, \*343  
  protein, \*154  
  and salicylate injections, \*77  
  of substrates in kidneys, \*550  
  thyroxine, 192-195  
  and tolbutamide, oral and intravenous, 543-48

## METAHEXAMIDE

alpha globulin bound, S19-22  
Bratton and Marshall procedure analysis, S19  
equilibrium dialysis, S19  
insulinogenic potency, S12  
toxicity, 89, 94, 216

## METFORMIN, \*345

## METHANDIENONE, and carbohydrate metabolism, \*549, \*550

## MICROANEURYSMS

See also Blood vessels, Retinopathy  
in capillaries  
  extraretinal, 8-9  
  retinal, 4-14, 126-130  
  and mesodermal bridges, 17, 126-130  
  and pericyte degeneration, 8  
  sites, 4-11

and corticotropin therapy, 18  
and perianeurysmal exudates, 12  
retinal  
  and hypophysectomy, 487

## MICROSCOPY

electron  
  of adipose tissue, 380-385  
  beta cell  
    degranulation, 427-429, S3-4  
    insulin determination, 104, S1  
  cellular hyperactivity effects, S5  
  of islets of Langerhans, 509-513  
  of mitochondrial membranes, 382-383  
  muscle biopsies, \*353  
  of renal glomeruli, 9  
  of renal lesions, 199, 291-294  
  of retinal tissue, 2-4, 126  
  of teleostean pancreatic islet tissue, \*247  
glomerulosclerosis, pathogenesis of, 308-317  
light  
  beta cell degranulation, 427-429, S3  
  muscle biopsies, \*353

## MORTALITY

and cholelithiasis surgery, \*252  
and complications, diabetic, \*346  
diet, low-protein, \*250  
from hyaline membrane disease, \*249  
ketosis, \*73-74  
perinatal  
  improved management, \*551  
  and insulin therapy, S99-100  
  and pregnancy, diabetic, \*76, \*152, \*156, 321-324, \*444, \*549  
  and sulfonylureas, S99-100  
  postoperative in retinopathy, 491-492  
  by race, sex, and age, 66

## MUCORMYCOSIS, \*155

## MUCOVISCIDOSIS, \*75

## MUHLBERG, William, 340-341

## MUSCLE

fiber loss in retina, \*156  
glucose  
  metabolism, 366  
  uptake  
    regulation, \*76  
    and sulfonylureas, S45  
heart, and carnitine action, \*248  
hexokinase inhibitor, \*76  
insulin  
  and adrenalectomy, 175  
  physiologic effect, \*443  
lipodystrophic hypertrophy, \*77  
sarcolemmal nuclei increase in fibers, \*353  
striated  
  d-galactose entry, \*550  
  fatty acids utilization, S66  
  sugar transport, 171-177

## MYOCARDIUM

glucose uptake, \*547

infarction and hyperglycemia, \*251  
metabolism, \*152  
and oleic acid, \*549

## N

### NATAL INDIANS

diabetes incidence, \*343  
pregnancy, diabetic  
  and chlorpropamide therapy, S99-100  
  and tolbutamide therapy, S99-100

### NECROSIS

bone changes, \*76  
fat, subcutaneous, \*351  
renal papillary, \*157, \*246

### NEPHROPATHY

and glomerulosclerosis, diffuse, \*440  
and hypophysectomy, 462, 471, 473, 481  
and immunologic process, 304-306  
in Japan, 538  
without manifest diabetes, 197-199  
steroid-induced, in rabbits, 402-410

### NERVOUS SYSTEM

galactosemia, \*552  
relation to disease, 191, 215

### NETHERLANDS NEW GUINEA, MULLIA REGION, cretinoid, hypothyroid syndrome prevalence, \*442

### NEUROPATHY

classification and therapy, \*77  
and growth-onset diabetes, \*152-153  
and hypophysectomy, 478  
and hypotension, postural, \*352  
and ischemia, \*76  
and procaine therapy, \*444  
and sprue, nontropical, 391

### NEW ENGLAND town, incidence of diabetes, \*252

### NEW YORK DIABETES ASSOCIATION CAMP, \*74, \*249

### NOREPINEPHRINE

fatty acids, hepatic uptake, 223-225  
and insulin, 396, 421  
measurement by Von Euler and Floeding method, \*72

### NUTRITION

See also Diet  
Argentine Congress on, 260  
and cirrhosis, \*152  
in diabetes management, \*74, \*157

## O

### OBESITY

and anorexigenic therapy, \*74  
and corticotropin secretion, \*74  
and diabetes incidence, 46-47, \*156

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150



# SUBJECT INDEX 1962

and diethylpropion, \*549  
and glucose tolerance, pathologic, \*352  
goldthiogluconate induced, 209-214  
hereditary and induced, 212-213  
and hyperglycemia, \*551  
and insulin antagonists, \*352  
low incidence in tropical diabetes, \*346  
and phenmetrazine hydrochloride, \*74  
and sex factor in diabetes, \*151  
and tolbutamide response, S37-38  
and total fasting, intermittent, \*547

OHIO STATE UNIVERSITY, study of  
retinopathy, 1-22

ORAL HYPOGLYCEMIC AGENTS  
See Sulfonureas, specific compounds

OXYGEN  
consumption, \*249  
and carbohydrate intake, \*250  
glucose effect, \*155  
insulin effect, 422  
and retinal vascular reactivity, \*74

## P

PANCREAS  
and alloxan toxicity, \*442  
alpha cells  
beta cell ratio, S118-119  
glucagon source, 372  
beta cells  
degranulation  
after acetohexamide, 84  
after tolbutamide, S2, S105-106,  
S118  
and insulin  
determination, 99, 104, S1-2  
volume, S107-108, S118  
carcinoma, tolbutamide test, \*246  
cystic fibrosis, \*73, \*343  
in children, S136  
and glucose, venous, 505-506  
and hyperglycemia, \*158, 325  
infant blood glucose response, \*245  
insulin  
after carbutamide perfusion, S81  
free, secretion of, S34  
after glucose perfusion, S81  
and butylbiguanide, S82  
-like activity  
and tolbutamide, S1  
output during pregnancy, 420  
release and sulfonureas, S12  
secretion into venous blood, \*349  
islet cells  
adenomas, \*156, \*250, \*439, S40,  
S136  
and leucine administration, 397-  
400  
and neuropsychiatric problems,  
\*72  
diet effect, \*551  
dissection, 97-98  
enlargement in newborn, S100  
histochemistry, S3-4  
microchemical studies, 96-100  
and sulfonureas, S66, S81

tolbutamide effect, S115-120, S125  
ultrastructure in rabbits, S3  
islets of Langerhans  
fluorescent insulin staining, 375-376  
and insulin, free and bound, \*443

tumors  
corticotropin-secreting, \*74  
removal, \*552

PANCREATECTOMY, \*77  
acetohexamide effect, 84-85  
and brittle disease, 118  
and chlorpropamide and leucine ad-  
ministration, 397-398  
and glucagon reaction in baboon, \*158  
and growth hormone, 426-433  
and hyperglycemia, \*247  
and insulin requirement, 118  
and liver mitochondria, \*343, \*546

PAPERCHROMATOGRAPHY  
in mellituria detection, \*246  
radio technic, \*249  
radioactive metabolites, study of, \*155

PEPTIDES  
bonds, hydrolysis of, 273-274  
in urine, \*246

pH  
See Hydrogen ion concentration

PHENETHYLBIGUANIDE, \*153-154  
See also Phenformin

PHENFORMIN  
See also Phenethylbiguanide  
as adjuvant oral therapy, \*72  
alphanaphtholdiacetyl reagent, \*248  
in biologic fluids and tissues, \*248  
with chlorpropamide  
or tolbutamide, \*343  
dosages, S90  
in gastrointestinal side effect pre-  
vention, \*343  
failures, \*249, S88-89  
excretion, S51-54  
production, S16-17  
hypoglycemic action of, \*72  
and insulin, \*155-156  
glucose threshold, 282-286  
and nitrogen balance, S51-54  
oxidative enzymes, effect on, \*153  
and placebo study, \*153  
side effects, S88-89  
and stress, metabolic, S90  
timed-disintegration capsules, \*153,  
\*348  
and ketoacidosis, \*160  
and stable diabetes, \*551  
with tolbutamide, S77  
or chlorpropamide, \*343

PHLORIZIN  
and glucosuria, \*249  
and insulin, \*550

PITUITARY  
function  
and hypophyseal stalk section, 465-  
468

hormonal increase during pregnancy,  
18  
and hyperglycemic action of glucagon,  
\*158

and hypophysectomy, 461-462  
insufficiency and retinopathy, 491-492  
and insulin antagonists, \*352  
and yttrium implants, 482-483

PLACENTA  
carbohydrate metabolism, \*248  
chlorpromazine and tolbutamide trans-  
fer, S93-96  
insulin-degrading factors, 420

PLASMA  
amino acid level in alligator, \*247  
carbon dioxide combining power in  
diabetic acidosis, 24-26  
fatty acids, 222-225  
removal, \*347  
glucose  
after phlorizin, \*249  
uptake and albumin, \*351-352  
glycerides  
and diet, 339  
growth hormone effect, \*346  
glycoprotein levels, 18-19  
inorganic phosphorus increase, 325  
insulin, \*157  
activity, 504-506  
-binding capacity, 166-168, 527-532  
disappearance, S38  
after hypophysectomy, 176  
and insulin resistance, \*73  
-like activity, 181, 261-266  
after L-leucine, \*440  
after tolbutamide, S138  
transport, \*443  
iron levels, \*251

POTASSIUM  
and acidosis, diabetic, 24  
and insulin, \*245  
liver content, \*156, \*245

PREDIABETES  
definition, \*73, 334, 335  
and genetic diabetogenic influence,  
335  
glucose tolerance tests  
cortisone, 50-51  
steroid, \*73  
and homozygosity, 56  
and insulin  
antagonist, 70  
-like activity in serum, \*158  
and menarchial age, 288-289  
and mucoviscidosis, \*75  
in pregnancy, 227, \*444  
and tolbutamide transfer, S93-96  
and toxemia, \*72  
and protein synthesis, 145  
and thiazide therapy, \*251  
and tolbutamide response, S138

PREDNISOLONE  
and blood sugar levels, 107-108  
histological effects, 402-410  
and insulin sensitivity, \*343-344

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

## PREDNISONE

- histological effects, 402-410
- and I-C-14-acetate, \*157
- and insulin
  - dosage, 166
  - requirement, 125, \*348

## PREGNANCY

- in diabetics
  - and azepinamide, S144
  - and carbohydrate
    - metabolism in rats, \*248
    - tolerance tests, \*72, \*152
  - and carbon dioxide pressure, \*347
  - and estrogen excretion, 514-518
  - and hormonal imbalance, \*152
  - and hypophysectomy, 471
  - management, \*72, \*152, \*444, \*551
  - and perinatal mortality, \*72, \*152, 321-324
  - and phenmetrazine hydrochloride therapy, \*74
  - and reproductive wastage, \*346
  - and tolbutamide, S93-96, S97-98
- diabetogenic effect, 419-420
- glucose
  - tolerance, \*158, 227-228
  - utilization, \*158
- and insulin metabolism, \*344
- and retinopathy, 18

## PRETOLBUTAMIDE

See Serum tolbutamide

## PROTEIN

- binding
  - of hexosamine, 18
  - of sulfonylureas, S18-25
- catabolism evaluation, \*248
- glucose carbon incorporation, \*249
- leucine incorporation, \*348
- loss through glomerular filter, 293

## PYELONEPHRITIS, \*549

- and hypophyseal stalk section, 466

## PYRUVATES

- disposal by fetal liver, \*248
- glycogen, conversion to, 365-366
- and intracellular block, \*548
- metabolism, \*159, S44
- tolerance after phenformin, 285

## R

REED, John Alton, 438-439

## RETINA

- See also Retinopathy
- basement membranes
  - and pericytes, 2-3
  - thickening, 9
- blood vessels
  - dilatation in rats, \*156
  - reactivity, \*74
- capillary mesodermal bridges, 127
- cribriform plate section, 11-12
- cystoid degeneration, 13
- hemorrhages in layers, 14
- microaneurysms, 375

- necrotic foci, \*351
- nervous elements
  - degeneration, 12-17
- thrombosis, 126

## RETINITIS PROLIFERANS, 484-485

- and adrenalectomy, 487-489

## RETINOPATHY

- and adrenal cortex
  - function, 17-18
  - hyperfunction, 31
- blastoma
  - trypsin digestion preparation, 126-128
- blindness, degree of, 483-484
  - and adrenalectomy, 485-490
  - and hypophyseal stalk section, 468
  - and hypophysectomy, 462, 463, 470, 471, 479
  - and nervous element degeneration, 14-17
- capillary
  - electron microscopy, 2-16
  - lumen changes, 7-11
  - pressure, 126
- and choroidal arteriosclerosis, 17
- and cystoid degeneration, 13
- and duration of diabetes, 538
- estrogen therapy, \*250
- extravascular changes, \*252, \*351
- exudates, 12-14
- glial degeneration, 14-17
- and glomerulosclerosis, diffuse, \*440
- and growth-onset diabetes, \*152-153
- hemorrhagic, 466
  - and hypophyseal stalk section, 467
  - and hypophysectomy, 461-462, 463-464
  - hemorrhages, effect on, 469
  - metabolic effect, 470-472
  - ophthalmological changes, 467, 469, 476-477
- and hypotension, postural, \*352
- ischemia, 130
- mesodermal bridges, 126-130
- and metabolism, \*74
- microaneurysms, \*247, 473
  - in adolescents, 109
  - hyaline depositions, 6-7
- and neovascularization, 5, 7, 126-130, 484, 488
  - in vitreous body, \*247
- nervous element degeneration, 14-17
- and pituitary insufficiency, 491-492
- retinal turgescence, 130

## RHINORRHEA

- and nasopharyngeal approaches, 488
- from yttrium implantation, 483

## RIBONUCLEIC ACID, and insulin, \*546

## S

## SALICYLATES

- binding, \*350
- and carbohydrate metabolism, \*151

- and glucose, labeled, \*77
- and glucose-6-phosphatase, \*151
- and hypoglycemia, \*349, \*443
- insulinogenic potency, S11
- long-term therapy, \*344
- and sulfonylureas, unbound, S18-24

## SEMEN, deficiency in diabetics, \*349

## SERUM

- and acetohexamide, 83
- alkaline phosphatase and sulfonylureas, 220
- anti-insulin
  - from animals, 519-520
  - and blood sugar, S26-33
  - and insulin, S29-30
  - and lipids, \*553
  - and tolbutamide, S1, S26-33
- beta lipoprotein level, 89
- bicarbonate, 29
- bilirubin level, \*249
- and cationic exchange resins, \*245
- cholesterol, 65
  - after acetohexamide therapy, 88
  - in controlled diabetics, S58
- heat labile factor, 183-191
- human
  - and hypoglycemia, 523-524
  - and sulfonylureas, bound, S21-22
- insulin, \*73
  - antagonists, 102, 124
  - dosages, effect of, 23, 29
  - after fasting, 265-266
  - immune and tolbutamide, S29-30
  - like activity, \*158, 179, \*247, \*343
  - and glucose injection, \*548
  - during pregnancy, 419-420
  - and tolbutamide, S1, 511-512
  - manometric assay, \*245, 419
- lipids
  - chlorothiazide effect, \*441
  - after fasting, \*252
  - in Hiroshima survey, 539
  - and insulin, S56
  - and nephropathy, 410
  - and tolbutamide, S56
- and liver glycogen disease, \*550
- phenformin content, \*248
- phosphorus, 29-32
- polysaccharide metabolism, 293
- proteins
  - antibodies in gamma globulin, 124
  - bound insulin, \*245, \*442
  - bound iodine, 192-195
  - electrophoretic patterns, 105-107
  - glycocorticoids and corticotropin effects, 105-108
  - and sulfonylureas, bound, S18-22
  - types of, and diabetes, 339-1
- salicylate ion, binding of, sulfonylurea concentrations, tolbutamide, S94-95
- urinary gonadotrophin level in pregnant diabetics, \*152

## SIDEROSIS, in the Bantu, \*251

## SIMMOND'S DISEASE, 18

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

## SKIN

- allergies
  - and insulin, 124
  - and sulfonylureas, 92-93
  - and tolbutamide, S78
- and azepinamide, S144, S146
- blood vessel alterations, \*441
- glycogen metabolism, \*151
- radiation effect, \*151
- surface-glucose test, 49-51, \*76, 202-203

SOMOGYI-NELSON METHOD, 24, 49-50, 53, 87, \*154, \*158, 204-208, 217, 222, 426, S37, S94, S116, S135

SOUTH AFRICA, DURBAN, diabetes incidence, \*343

SPINGLER TECHNIC, S19, S94

STE. TORRHEA, diabetic, \*252, 388-391, 436-437  
and jejunal biopsy, \*439, 503

## STERIODS

- and adrenalectomy and hypophysectomy, 489
- and carbohydrate metabolism, \*549
- and glomerular changes, 405-407
- and hypophosphatemia, 31-34
- and insulin resistance, 125, 165-169, \*352
- and mitotic figures, 35
- nephropathy, 402-410
- urinary assays, \*548

## STRESS

- and glycosuria, 213
- metabolic, and tolbutamide, S77, S90
- and protein-bound carbohydrates, 18
- and temporary diabetes, 334

## SUGAR

- See Blood Sugar, specific substances

SULFADIAZINE, insulinogenic potency, S12

SULFATHIAZOLE, S22

## SULFONYLUREAS

- See also specific compounds
- age factor in pregnancy, S100
- AH 6848 (methoxypropyl-sulfonylurea), S16-17
- BH 135, \*439
- and claudication, intermittent, \*553
- derivatives, effect of, S66
- and "diabetic" index, \*442-443
- and facial flushing, 41
- failures, S81-82
- and glucose uptake, S45
- hematopoietic system, effect on, \*346
- hepatic action, 507
- and hypercholesteremia, S69-72
- and hyperlipemia, S69-72
- hypoglycemic
  - and hepatic glucose release, S16-17
  - potencies, 220
  - tolazamide, 216-221

## and insulin

- hepatic action elucidation, S14
- release, \*349, S2, S12, S66, S115
- resistance, \*151, \*552
- therapy, \*248
- insulinogenic potencies, S11-12
- and islet cells, S118, S125
- exhaustion, S81
- growth, S83
- nonhypoglycemic
  - and hepatic glucose release, S16-17
  - pharmacology, comparative, \*348, \*552
  - in pregnancy, diabetic, S99-100
- protein interactions
  - in different animal species, S18-24
  - and stable diabetes, \*551
- tolazamide, 216-220
- in treatment, \*72, \*153-154, \*155-156, 216-220
- long-term, \*252, S80-84
- of maturity-onset diabetes, \*249
- of nonobese patients, 89
- and severity of diabetes, S50-53
- and tropical diabetes, \*346

## SURGERY

- for cholelithiasis in diabetics, \*252, \*444
- complications in diabetics, \*73
- criteria in retinopathy, 491-492
- for fibrous mesothelioma, \*548
- and gangrene, diabetic, \*346, \*547
- hyperinsulinism, \*74-75
- for hyperplasia correction, \*248
- hypophysectomy
  - mortality, 461, 463, 469, 470, 473, 480
  - operative procedure, 474, 479
  - and orthostatic hypotension, 478
  - preoperative evaluation, 463, 466, 471, 473
  - and vascular complications, 462
  - and isolated limb perfusion, \*250
- management
  - and hyperinsulinism, \*74-75
  - and physiochemical imbalance, \*344
  - pre- and postoperative, \*72

SWEAT, sodium and chloride concentration, \*75

## T

TEMPERATURE, and glucose transfer, \*349

TES-TAPE TEST, 53-55, \*345

## TESTS

- See specific tests

TETD. Tetraethylthiuram disulphide, 40-42

THIAZIDES, diabetogenic effect, \*251

## THROMBOSIS

- and fibrinolysin, \*250
- retinal
  - in microaneurysms, 6-7
  - in small veins, 126

## THYROID

- function after hypophysectomy, 475
- insulin stimulation of, 195

## THYROXINE

- metabolism and insulin, 192-195
- and muscle glucose utilization, 176

## TISSUE

- acinar
  - enzyme activity, S5, 98-99
- adipose
  - acid metabolism, \*546
  - from alloxan-diabetic rats, \*78
  - amino acid incorporation, 145
  - cortisol effect, \*550
  - epinephrine effect, \*247
  - from fasted and diabetic rats, 378-386
  - fatty acid composition, \*549
  - and free fatty acids, 224-225, \*347, \*352
- glucose
  - uptake, \*76, 179, \*246, \*352
  - utilization, S64-66, \*440
- and insulin
  - bound, \*245
  - free and complex, 262-264
  - free, dissociation of, S34
  - physiologic effect, \*443
  - response impairment, 177
  - sensitivity, \*247
- carbohydrate metabolism, \*248, 422-425
- hypoxia in infants, \*351
- islet
  - and caloric intake, \*551
  - carbohydrate metabolism, \*154-155
  - insulin assay, \*245
  - volume and tolbutamide, S107
- mouse mammary
  - and insulin and cortisol, \*250
- myocardial
  - glucose uptake, \*547
- peripheral
  - carbohydrate utilization and tolbutamide, S66
  - glucose threshold, 281-282, S44
  - pyruvate level, 285
  - phenformin content, \*248
  - tumor, hypoglycemic factor, \*350

## TOLAZAMIDE

- clinical evaluation, 216-220
- and pregnancy, diabetic, S144-145
- tolbutamide and chlorpropamide, comparison with, 218

## TOLBUTAMIDE, \*153-154, \*349

- and Addison's disease, \*78
- and adenosine triphosphatase, S8
- albumin and pre-albumin fraction bound, S19-22
- beta cells, effect on, S1, S2, S5, S105-106, S118, 510-511
- and blood
  - lipids, S71
  - sugar, \*348, \*352, S62-68, S71

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150

# SUBJECT INDEX 1962

in body water, 89  
in cancer detection, \*439  
in carcinoma diagnosis, \*246  
in childhood diabetes, 125, S77  
comparison with azepinamide, S143  
chlorpropamide, S67  
insulin, S26-33  
tolazamide, 218  
dosages, 84, S77, S90  
and edema, nephrotic-like, \*443  
ethanol metabolism, effect on, \*442  
failures, \*72, 92, 95, \*344  
primary, S81, S88-89, S143, \*546  
secondary, S76, S81, S89, S143, \*546  
fatty acids, effect on, S62-68  
and gastric secretion, \*352  
and hepatic glucose release, S16-17  
and hepatitis, \*349  
histochemical studies, S2-8  
hypoglycemia, \*552  
and immune serum, S29-31  
and insulin  
degranulation and reduction, S46  
-immune rabbits, effect on, S28-29  
liberation, S5-6, S34  
regulation, S34-35  
resistance therapy, S35-41, \*552  
secretion, S06-507  
insulinogenic potency, \*343, \*349, S11-12  
in insulinoma detection, \*250  
and islet weight, S115-120  
and hypophysectomy, S119  
and leucine, \*547  
long-term  
study, S74-79  
therapy, \*252, S103-114  
and maturity-onset diabetes, S70, \*551  
with metformin or insulin, \*345  
in mild diabetes, S123-126  
and carbohydrate tolerance, S126  
and mouse viral hepatitis, \*349  
and nitrogen balance, S50-53  
oral and intravenous  
and blood sugar, S46-47  
and metabolism, peripheral, effect on, S43-48  
pancreatic cancer test, \*246  
with phenformin, \*343, S77  
and prediabetes, \*350  
and pregnancy, diabetic, S99-100  
detection, S97-98  
management, S97-98  
and renal toxicity, \*443  
and severity of diabetes, S50-54  
side effects, S78  
and somatotropin, S118  
Spingler technic analysis, S19  
modification, S94  
testicular fat, effect on, \*158  
thrombocytopenic effect, \*346  
tolerance test  
in diagnosis, S132-135  
in infants and children, S135-137  
in prediabetes, S138  
toxicity, freedom from, S84-87  
ultramicroscopic studies, S2-8

TRANSHYDROGENASE, 271-278  
TRICHLOROACETIC ACID, end group  
analysis, 272-274  
TRIGLYCERIDES  
lipolysis, 225  
metabolism, S44  
in rat liver, \*346  
TRIIODOTHYRONINE  
and glucose uptake, 423-424  
and ketonemia, \*439  
TRIPHOSPHOPYRIDINE NUCLEO-  
TIDE, \*78, 97-98, 275-278,  
\*442  
and glucose-6-phosphate dehydrogen-  
ase deficiency, \*345  
TUMORS  
beta cell and insulin release, 510  
corticotrophin-secreting, \*74  
enzyme activity, S2  
glucose-uptake inhibitor, \*353  
hypoglycemic factor, \*350  
insulinomas and ulcerogenic, \*552  
islet cell and peptic ulcer, \*156  
kidney after steroids, 409-410  
retroperitoneal and hypoglycemia, \*548

## U

UNITED STATES NATIONAL HEALTH  
SURVEY, 67-68  
UREA, 1-(HEXAHYDRO-1-AZEPINYL)-  
3 - P - TOLYLSULFONYL -  
(TOLAZAMIDE)  
See Tolazamide  
UREA, 1-(PARACHLOROPHENYLSUL-  
FONYL) - 3 - (HEXAHY-  
DRO-1-AZEPINYL-)  
See Azepinamide  
URINE  
acetone  
after exercise, \*74  
and insulin resistance, \*73  
adrenalin, \*159  
albumin, S85  
epinephrine, \*72  
after adrenalectomy, \*159  
and norepinephrine, 396, 421  
estrogens, 514-518  
fat metabolizing substance, \*246  
galactose, \*553  
Hobkirk's modification of Bauld's meth-  
od, 514  
b-hydroxybutyric acid, \*157  
5-hydroxyindolyl acetic acid, 41  
17-hydroxysteroids, 487  
infections, urinary tract, 539  
ketones, 537  
nitrogen, 538  
and phenformin, S51-54  
peptides, \*246  
phenformin content, \*248

plasma amino acids, \*247  
in pregnancy  
estriol excretion, \*351  
estrogen and pregnandiol, \*152  
protein, 484, 538  
and hypophysectomy, 463, 477  
steroid assays, \*548  
sugar content, \*246  
and acetohexamide, 83  
and chloramphenicol, \*345  
comparative test values, 53-55  
and cortisone, 211  
in detection survey, 44-45, \*155,  
534  
after phenformin, \*72  
and pituitary function, 492  
and tolbutamide, S104  
sulfonyleureas excretion, 87  
sulfur, \*551  
URISTIX, 53-55

## V

VASOPRESSIN, 277  
VON EULER AND FLODING METH-  
OD, \*72  
VON GIERKE'S DISEASE, enzyme de-  
fect, \*441, \*547

## W

WEIGHT  
and fetal loss, 321-323  
gain  
after chlorpropamide therapy, 94  
and tolbutamide, \*443  
in Increment Index, S128  
insulin assay, effect on, 414  
loss, \*72, \*250  
after adrenocorticosteroids, 107  
and phenmetrazine hydrochloride  
therapy, \*74  
total fasting, intermittent, \*547  
and triamcinolone, \*443  
and sex, 536  
WINNIPEG GENERAL HOSPITAL,  
\*72  
WORLD HEALTH ORGANIZATION  
resolution, 150-151

## Y

YTTRIUM IMPLANTS  
and pituitary destruction, 464  
for retinopathy, 482-483  
patient selection, 483

## Z

ZINC, insulin association, \*248  
ZOLLINGER-ELLISON SYNDROME,  
\*73  
ZULUS, diabetes incidence, \*343

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150



# AUTHOR INDEX 1962

In this index are the names of authors of articles that have appeared in *DIABETES* and those whose articles have been abstracted in the Journal during 1962. Entries marked with an asterisk (\*) indicate authors of material that appeared in the *ABSTRACTS* only. Those preceded by the letter "S" refer to the Volume 11 Supplement entitled *Tolbutamide Therapy after Five Years*. The Subject Index appears on page 1.

## A

Abboud, Francois M., \*348  
Abelove, William A., 216-221, S142-146  
Abend, Melvin N., \*343, \*546  
Abt, Arthur F., \*342  
Ack, Marvin, \*342  
Acland, J. D., \*245  
Adachi, Kenji, \*151  
Adams, Levi C., \*346  
Adams, Reuben H., \*73  
Ainslie, D., 463-464  
Akedo, Hitoshi, \*342  
Alexander, James D., 412-418  
Allen, Frederick M., 336-338  
Altman, Morris, \*546-547  
Altmann, G., \*342  
Altszuler, Norman, \*153, \*249  
Amatruda, Thomas T., Jr., \*439  
Andersen, H. C., 474-479  
Anderson, George E., \*72  
Anderson, Paul S., Jr., 533-543  
Anderson, R. C., 83-90  
Anderson, Robert S., \*151  
Andres, Ruben, \*245  
Andrews, Muriel M., \*151  
Antoniades, Harry N., \*245, 261-270, S34-35, S42  
Appels, Anton, 465-469  
Arab, M. M. H., S43-49  
Arbus, G. S., \*549  
Arquilla, E. R., 183-191, \*342-343, 412-418  
Ashe, Benjamin I., \*153  
Ashmore, James, \*159  
Ashton, Doris M., \*441  
Auld, Peter A. M., \*249  
Auld, W. H. R., \*345  
Austen, K. Frank, \*443

## B

Back, N., \*350  
Bahn, Robert C., \*350  
Bailey, Donald W., \*249  
Baird, Joyce D., \*245  
Balash, W. R., 31-34, \*547  
Ball, Eric G., \*245  
Balodimos, Marios C., \*245  
Baltzan, Marcel A., \*245  
Banerjee, Gouri, \*159  
Banfield, P. J., \*348

Bank, H., \*342  
Barden, Herbert, \*442  
Barnes, P. H., \*72  
Barrett, James C., \*343, S35-41  
Barton, S. M., \*342-343  
Bastenie, P. A., \*548  
Bateman, J. R., 183-191  
Baum, John, 371-374  
Baxter, N., \*349  
Bayrd, Edwin D., \*350  
Beaser, Samuel B., S74, S103, S147  
Beck, John C., \*343  
Becker, Bernard, 375-377  
Beigelman, Paul M., 179-182, 183-191, 261-270  
Belcher, Henry V., \*548  
Bellens, R., \*548  
Benbassat, J., \*345  
Bencosme, Sergio A., 402-411  
Benedek, Thomas G., \*251  
Benitz, K.-F., \*158  
Bennett, Leslie L., \*155  
Bentor, Victoria, 422-425  
Berkowitz, Donald, \*246, \*439, S56-61, S73, S141  
Bern, Howard A., \*250  
Bernhart, F. W., \*246  
Berns, A. W., 296-307, 308-317  
Berson, Solomon A., \*151, \*160  
Bessman, Samuel P., 23-30  
Best, Charles H., \*439, 495-503  
Bewsher, P. D., \*252, S127-130  
Beyer, Robert E., \*343, \*546  
Bianco, A. R., \*348-349  
Bickel, Horst, \*246  
Bingle, J. P., \*439  
Bishop, Raymond H., Jr., \*155  
Blackard, William G., \*352  
Blahey, P. R., 514-518  
Blair, Alberta, \*157  
Blanshard, Gerald, \*76  
Blitz, Milton, \*248  
Bloodworth, J. M. B., Jr., 1-22, \*151-152  
Bloom, Arnold, \*72  
Bloom, Walter L., \*441  
Blumenthal, Herman T., 296-307, 308-317, S11, S26-33, S43  
Blumsohn, D., 202-203, S98-101  
Bonessi, J. V., \*547  
Bookman, John J., S97-98  
Bortz, Walter, \*246

Boshell, Buris R., \*152, \*158, \*343, S35-41, S147  
Bothwell, T. H., \*251  
Bougas, James A., 261-270, S34-35  
Bowers, C. Y., \*246  
Brackenridge, R. G., S127-130  
Bradley, Robert F., S88-91  
Bradshaw, Marie, \*442  
Brager, Stuart H., 23-30  
Brandstrup, Ebbe, \*72, \*152  
Breidahl, H. D., \*343  
Bremer, J., \*548  
Broberger, O., \*72  
Bronstein, Seymour, \*159  
Brooks, Frank P., \*547  
Brown, Arnold L., Jr., 388-392  
Bruno, Michael S., \*439  
Bruns, Paul D., \*351  
Bryan, John B., \*160, 472  
Buchan, D. J., \*439  
Buckle, A. L. J., S43-49  
Buckle, Richard M., \*343  
Burgess, L., \*440  
Burgess, T. L., \*440  
Burt, Richard L., 227-228, 419-421  
Butler, Frank K., \*252  
Butterfield, W. J. H., \*72, \*72, 281-286, \*548, S43-49

## C

Cader, Gordon, \*245  
Cady, Lee D., Jr., \*351  
Cahill, George F., Jr., \*78, \*246, 318-320, \*550, \*550, S130  
Camerini-Dávalos, Rafael A., \*158, \*546, S74-80, S92, S147  
Camiel, Mortimer R., \*152  
Campbell, G. D., \*343, S98-101  
Camperlengo, Henry A., \*72-73  
Canaan, Samuel, 375-377  
Carlsten, A., \*152  
Carpenter, Anna-Mary, S103-115  
Carr, James H., Jr., \*343  
Carruthers, Bruce M., \*546  
Castenfor, H., \*152, \*155  
Castrillon, A. M., \*440  
Chalmers, T. M., \*246  
Charles, Rene N., \*73, \*343  
Chase, Joan W., \*439  
Chase, Tom P., 393-396

## DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume 11 Supplement, 1-150

# AUTHOR INDEX 1962

Cherry, Ruth B., \*249  
 Chiowanich, Pien, S135-137  
 Chlouverakis, C., S43-49  
 Chow, Donald C., \*151  
 Christensen, Halvor N., \*342  
 Clayton, H., \*245  
 Clifford, Nathan J., \*343  
 Clifford, Ruth C., \*154  
 Cogan, David G., \*246-247, \*252, \*351  
 Cohen, Alan S., 204-208  
 Cohen, Nathaniel, \*73  
 Coleman, Stan L., 375-377  
 Collens, William S., \*546-547  
 Collyer, Robert T., \*152-153  
 Colwell, Arthur R., Jr., 504-508  
 Colwell, Arthur R., Sr., S13, S50-55, S55, S92, S101, S130, S147  
 Combes, Burton, \*73  
 Conard, V., \*548  
 Conn, Jerome W., 335, S123-126  
 Constam, Georg, 138-143, 228-235  
 Cooke, J. N. C., \*549, \*549-550  
 Comblath, Marvin, \*153  
 Correa, P. Riet, \*247  
 Cotton, L. T., \*553  
 Coulson, Roland A., \*247  
 Coyle, Maurice J., \*252  
 Creutzfeldt, Werner, \*343-344  
 Cristofori, Fred C., \*547  
 Cunningham, Paul, \*552

## D

D'Amato, Elisa, \*246  
 Danforth, W. H., \*547  
 Danowski, Thaddeus S., \*73, 239-240, \*547  
 Davidson, John K., S115-120  
 Davis, Richard A., \*547  
 Davis, Thomas R. A., \*444  
 de Alvarez Buylla, Elena R., \*342, \*342  
 de Alvarez Buylla, R., \*342  
 De Bodo, Richard C., \*153  
 De la Harpe, P. L., \*73  
 Deuticke, Ursula, \*343-344  
 Di George, Angelo M., S131, S135-137  
 Litschuneit, Hans, S12, S13, S42  
 Ditturi, Bessie, \*153  
 Dobkin, Gerald B., \*546-547  
 Dobson, Harold L., \*154, S102  
 Dolger, Henry, S97-98, S101, S130, S146  
 Dolkart, Ralph E., 519-526  
 Dominguez, J. M., 469-470  
 Doray, B. H., \*550  
 Dotevall, Gerhard, \*344, \*344  
 Drapkin, Arnold, \*344  
 Dreiling, David A., \*73  
 Drorbaugh, James E., \*249  
 Drose, Vera E., \*351  
 Drucker, William D., \*547  
 Duncan, Garfield G., \*547

## E

Eberlein, Walter R., \*547  
 Echenique, Raul, 216-221, S142-146  
 Eckstein, John W., \*348

Egdahl, Richard H., \*247  
 Eisentraut, A. M., \*347  
 Ekengren, Kristina E. K., 109-117  
 Eldjarn, L., \*548  
 Eliasch, H., \*152  
 Elkins, Carol M., \*441  
 Ellenberg, Max, 197-201  
 Elliott, F. A., \*353  
 Engel, Frank L., \*352, \*439  
 Engel, Lewis L., \*548  
 Enquist, Irving F., \*250  
 Etzwiler, Donnell D., \*247, \*548  
 Ezrin, Calvin, \*548

## F

Fabrykant, Maximilian, \*153  
 Fajans, Stefan S., \*73, 335, S49, S102, S122, S123-126, S130, S139  
 Falkner, Sture, \*247  
 Farquhar, James W., \*73, \*245  
 Felbo, M., \*76, \*156  
 Ferguson, Arthur W., \*73  
 Ficarra, Bernard J., \*344  
 Field, James B., \*73, 165-170, \*247, \*440  
 Field, Richard A., \*346, \*444, 465-469, S141  
 Finch, Stuart C., \*551  
 Finlay, J. M., \*252  
 Fish, Gilbert D., Jr., \*153, \*248  
 Fitch, Ray F., \*547  
 FitzGerald, M. G., 40-43, \*73-74  
 Fitzpatrick, Hugh F., \*250  
 Flanders, Eric, \*342-343  
 Fleissner, Sylvia, \*552-553  
 Flute, P. T., \*553  
 Fosbrooke, Audrey S., \*550  
 Fosnaugh, Robert P., \*346  
 Fowler, A. F., 514-518  
 Francis, John O'S., 204-208  
 Franckson, J. R. M., \*548  
 Frantz, Virginia K., \*156  
 Fraser, Robert I., \*547  
 Fraser, Russell, \*77, 482-483  
 Freedman, Louis, \*248  
 Freinkel, Norbert, \*344  
 Friedman, Gerald J., \*74, \*344  
 Fritz, Irving B., \*160, \*248  
 Fry, I. Kelsey, \*72, \*548  
 Fugmann, Ulla, \*76

## G

Gaddie, R., 40-43  
 Gajdusek, D. C., \*442  
 Ganzon, Angelita F., \*153  
 Garcia-Fernandez, M. C., \*440  
 Garfield, Claude R., \*548  
 Gaston, J. Harper, \*547  
 Gellman, Derek D., \*440  
 Gersing, Albert, \*441  
 Gertler, Menard M., \*351  
 Ghitman, Bernard, \*441  
 Gilat, T., \*342  
 Gilgore, Sheldon G., \*344  
 Gittler, Robert D., \*248

Glasser, Elaine J., S18-25  
 Glasser, Stanley R., \*248  
 Glassman, Sol, \*246, \*439  
 Click, Seymour M., \*248  
 Gold, Martin, \*347, \*548-549  
 Goldberg, Harold, \*247  
 Goldman, Allen S., 122-125  
 Goldner, Martin G., \*154, \*553  
 Goldstein, Maurice S., \*442  
 Gomez, Ruben, 105-108  
 Goodell, R. A., Jr., \*344-345  
 Goodman, Joseph I., \*153-154  
 Goodner, Charles J., \*344  
 Gordon, Edgar S., 470-472  
 Gordon, Edwin E., \*154  
 Gordon, Harry H., \*153, \*549  
 Gordon, Mordecai H., \*153  
 Gottfried, Sidney P., \*154  
 Gottlieb, B., \*345  
 Graef, Irving, 485-490  
 Graig, Frank A., \*248  
 Granville, George E., \*251, \*350  
 Green, Paul A., 388-392  
 Greenac., E. R., \*345  
 Greenberg, E., 469-470  
 Greenberg, Leonard, \*246, \*439  
 Greenberg, Sigmond R., \*441  
 Griffin, A. Clark, \*154  
 Groen, J. J., \*345  
 Grundy, Scott M., \*154  
 Gumbel, W., \*75  
 Gundersen, Kare, \*69-71, \*245, 261-270  
 Gunsberg, Ephraim, \*248  
 Gunson, H. H., 329-333  
 Gunter, Laurie M., \*151  
 Gwinup, Grant, 397-401

## H

Hadden, David R., 91-95  
 Haft, David E., \*74  
 Hagerman, Dwain D., \*248  
 Hahn, Robert F., \*444  
 Haist, R. E., S115-120  
 Hallgren, B., \*152  
 Halpern, Bernard, 519-526  
 Handelsman, Milton B., \*74, \*441  
 Hanley, T., S43-49  
 Harding, P. C. R., 321-328  
 Harkness, John, \*441  
 Harter, Melvin M., 118-121  
 Hastings, A. Baird, 361-370  
 Haunz, E. A., \*248, \*345  
 Hausberger, F. X., \*74  
 Hazlett, Barbara E., \*74, \*152-153  
 Hecht, Arthur, \*154  
 Heimann-Hollaender, E., \*345  
 Heimberg, Murray, \*345-346  
 Heller, H., \*342  
 Hellman, Bo, \*154-155, \*249, \*551  
 Hendon, James R., \*441, \*549  
 Hernandez, Thomas, \*247  
 Herrera, M. Guillermo, \*249  
 Herring, Betty, \*73  
 Hetenyi, G., Jr., 236-239, \*549  
 Hickam, J. B., \*74  
 Higgins, F. E., \*439

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
 March-April, 83-164

May-June, 165-260  
 July-August, 261-360  
 Volume II Supplement, 1-150

September-October, 361-460  
 November-December, 461-562

AUTHOR INDEX 1962

Hills, A. Gorman, 216-221, S61-68, S142-146  
Hinden, E., \*549  
Hirata, Y., 44-48, 209-215, 296-307, 308-317, S26-33  
Hitselberger, James F., \*346  
Hoagland, Robert J., \*155  
Hoar, Carl S., Jr., \*346  
Hobkirk, R., 514-518  
Hoffman, David L., \*74-75  
Holding, Bruce F., Jr., \*155  
Hollenberg, H. C., 378-387  
Hollis, William C., \*75  
Holt, George W., \*549  
Horino, M., 44-48, 209-215  
Hososako, A., 44-48, 209-215  
Houghton, B. J., \*549-550  
Howell, Rodney R., \*441  
Hoxter, Gunther, \*159  
Hubbell, John P., Jr., \*249  
Hülsmann, W. C., \*75  
Hultman, E., \*152, \*155  
Humbel, Rene E., \*249  
Hunt, Ernest L., \*249  
Hurwitz, David, \*251  
Hurwitz, Gilbert E., 23-30  
Huston, C. J. W., \*346

I

Ibrahim, Md., \*346  
Ikkos, D., \*159  
Illingworth, Barbara A., \*547  
Isaacson, C., \*251  
Isham, William H., \*153, \*246  
Ishimoto, M., 44-48, 209-215  
Ito, M., 44-48, 209-215  
Izzo, Joseph L., \*248

J

Jackson, Robert L., \*75, 393-396  
Jackson, W. P. U., 202-203, 334, S93, S98-101, S102, S138  
Jacobson, Marshall H., \*549  
Jagenburg, R., \*152  
Jakobsen, L. Kramer, \*155  
Jakobson, Theodor, \*346  
Janowitz, H. D., \*73  
Javid, Manucher, 470-472  
Jensen, V. A., 474-479  
Jenson, William K., \*547  
Johnson, Phyllis, \*73  
Joplin, G. F., 482-483  
Joron, G. E., 514-518  
Jow, Eleanor, \*75  
Juhl, Ole, \*444

K

Káldor, Antal, S16-18  
Kantor, Nathan, 53-55, 204-208  
Kaplan, Eli, \*248  
Kaplan, Norman M., S84-87, S102, S141  
Kark, Robert M., \*440  
Kartchner, Max J., \*351  
Katsoyannis, Panayotis G., \*441

Katsuki, S., 209-215  
Katz, Isadore, \*343  
Katz, Louis N., \*77  
Katzen, Howard M., 271-280  
Kaye, Robert, 122-125  
Keeley, K. J., \*251  
Keller, P., S138  
Kelley, Maurice L., Jr., \*73, \*343  
Kennan, Alfred L., \*346  
Kennedy, A., \*549  
Kenny, Alexander D., \*441  
Kern, Lee R., \*348, \*551-552  
Kidson, C., \*442  
Kiern, Iris, S61-68  
Kinch, R. A. H., 321-328  
Kinsell, Laurance W., 338-339, \*346, 473-474  
Kipnis, David M., 171-178  
Kirtley, W. R., 83-90  
Kitzmler, George E., \*154  
Klausner, Howard, \*345-346  
Kleiber, M., \*351  
Kleiner, Israel S., \*553  
Kline, Robert, \*249  
Klotz, Roy G., \*441  
Koch, E., \*75  
Kokka, Norio, \*155  
Kolodny, Edwin H., \*249  
Korchak, Helen, \*250  
Korn, C., \*158-159  
Korner, A., \*249  
Krahl, Maurice E., 144-146, \*348  
Krall, Leo P., \*252, S88-92  
Krebs, H. A., \*75, \*353  
Kreisberg, Robert A., 519-526  
Kuhl, W. James, Jr., 118-121  
Kuwabara, Toichiro, \*246-247, \*252, \*351

L

Lacy, Paul E., 96-100, 101-104, 509-513, S1-2, S10  
Lancaster, Vance B., \*155-156  
Landon, J., \*549, \*549-550  
Lanese, Richard R., 132-137  
Langman, M. J., \*348  
Larsen, Jens A., \*442  
Larsson, Stig, \*154-155, \*249  
Larsson, Yngve A. A., 109-117  
Law, Sam W., \*251, \*550  
Lazarow, Arnold, S10, S42, S103-115, S121  
Lazarus, Sydney S., \*75-76, 426-435, \*442, S2-10, S15, S122  
Leake, Norman H., 419-421  
Leboeuf, Bernard, \*78, \*550  
LeCompte, Philip M., 35-38  
Lee, James B., \*550  
Lehmann, W., \*75  
Lepow, Martha L., \*443  
Levin, Ephraim Y., \*153  
Levine, Rachmiel, \*442  
Levitt, Leon M., \*76  
Lilley, M. D., \*351, \*352  
Linder, Morton, \*160, \*249  
Lloyd, June K., \*550

Lockie, G. N., \*350  
Logue, Valentine, 463-464  
Lomax, Nancita R., \*553  
Loosli, Edward S., 412-418  
Lotspeich, William D., \*550  
Loughlin, Winifred C., \*74, \*249  
Lowe, Charles U., \*550, \*552-553  
Lowrie, William L., \*160  
Lowy, Clara, \*76  
Lozano-Castaneda, O., S74-80  
Lucas, C., \*552  
Luft, Rolf, \*159, 461-462  
Lukens, Francis D. W., 43, 48, S13, S15, S42, S49, S55, S74, S92, S103, S121, S148  
Lumms, Frederick R., Jr., \*348, \*551  
Lundbaek, Knud, \*442-443, 474-479  
Lundquist, F., \*76, \*553

M

Macaulay, Alice I., \*249  
Macdonald, I., \*250  
MacDonald, Mary K., 291-295  
Madison, Leonard L., \*73, 371-374, S13, S14-15, S49, S84-87  
Madsen, Joop, \*442  
Magalhaes, E., \*247  
Maha, G. E., 83-90  
Mahler, R. F., S15, S43-49  
Mahon, W. A., \*347, \*550-551  
Maier, Herbert C., 485-490  
Makino, N., 44-48, 209-215  
Malins, John M., 40-43, \*73-74, 483-485  
Malmros, R., 474-479  
Mann, George V., \*551  
Marble, Alexander, \*158, \*546, S74-80, S91, S101, S146, S148-150  
Markowitz, Alfred M., \*156  
Marks, Bernard H., S61-68  
Marks, Herbert H., \*347, 544-545  
Marks, Paul A., \*78  
Marks, Vincent, \*250  
Marrack, David, \*250  
Martin, H. E., 183-191  
Martin, William J., \*347  
Masoro, E. J., \*250  
Massey, C. G., \*353  
Matchar, Joseph C., \*350  
Mazure, Pablo, \*73  
Mazzacca, G., \*348-349  
McCall, R. S., \*347  
McCarron, Margaret M., \*252  
McCormick, Donald B., \*156  
McDermott, W. V., Jr., \*346  
McElroy, William T., Jr., 222-226  
McGavack, Thomas H., \*347  
McHenry, John I., \*348, \*551  
McHenry, Martin C., \*347  
McKechnie, John K., \*343, \*347  
McKhann, G. M., \*347, \*550-551  
McKinsey, J. J., \*547  
McKittrick, Leland S., \*73  
Mehner, Hellmut, S13, S74, S80-84, S92  
Meriwether, Thomas W., III, \*353  
Merriam, Joseph C., Jr., 35-38  
Merrill, Margery A., \*245  
Mertz, Walter, \*443

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
March-April, 83-164

May-June, 165-260  
July-August, 261-360

September-October, 361-460  
November-December, 461-562

Volume II Supplement, 1-150

# AUTHOR INDEX 1962

Metz, Robert, 504-508  
 Michaels, George D., \*346  
 Mikkelsen, William P., \*252  
 Miller, David I., S93-97  
 Miller, Harvey I., \*347, \*548-549  
 Miller, Irving, \*342  
 Mitchell, B., \*245  
 Mitchell, M. L., \*347, \*550-551  
 Möller, Tage G. H. O., 109-117  
 Molnar, George D., 527-532  
 Montgomery, D. A. D., 91-95  
 Moore, Michael J., \*443  
 Morey, Emily R., \*441-442  
 Morgan, Carl, S103-115  
 Morriane, Thomas G., \*441  
 Morse, Jane H., \*347  
 Mortimer, Edward A., Jr., \*443  
 Mortimore, Glenn E., \*156, \*553  
 Moses, Campbell, 31-34, \*547  
 Mosier, H. David, \*153  
 Mosovich, Luis L., \*550, \*552-553  
 Muehrcke, Robert C., \*440  
 Muller-Ruchholz, W., S12  
 Mulligan, Paula B., \*443-444  
 Munroe, John F., S69-73  
 Murray, J. G., \*553  
 Musacchio, I. T. L., \*156

## N

Nabarro, J. D. N., 463-464  
 Naide, Meyer, \*76  
 Nechemias, Charles, S97-98  
 Nedelman, Philip B., \*347-348  
 Neely, Winston B., \*348, \*551  
 Neu, Leo T., Jr., \*252  
 Neumann, Edith, \*546-547  
 Newcomb, Alvah L., \*351  
 Newman, William, \*549  
 Newsholme, E. A., \*76  
 Nicholas, William C., \*548  
 Nicolopoulos, Demetrios, \*153  
 Nolan, James P., \*551  
 Norton, William S., II, \*553  
 Notelovitz, M., S98-101  
 Nusimovich, Bernardo, S56, S103  
 Nygaard, A., \*76, \*156

## O

Ober, William B., \*439  
 Oei, T. L., \*75  
 Olen, Else, \*552  
 Oleson, J., \*158  
 Olsson, Ragnar, \*247  
 Ooms, H.-A., \*548  
 Orht, V., 474-479  
 Osler, Mogens, \*72, \*152  
 Osserman, Kermit E., \*156  
 O'Sullivan, D. J., 40-43, \*73-74  
 O'Sullivan, John B., 53-55  
 Overstreet, A. Evan, \*250  
 Owen, Charles A., Jr., 527-532  
 Owen, John A., Jr., \*551  
 Owens, C. T., 296-307, 308-317  
 Owens, John C., \*348, \*551-552

## P

Palermo, N., \*156  
 Parker, Arthur M., 49-52  
 Parker, Virgil J., \*444  
 Passmore, R., \*76  
 Paton, Donald M., \*551  
 Paul, Jerome T., \*444  
 Pawan, C. L. S., \*246  
 Pazianos, A., 469-470  
 Pearson, O. H., 469-470  
 Pedersen, Jørgen, \*72, \*76, \*152, \*156  
 Peel, Sir John, \*444  
 Pegues, J. J., \*353  
 Pelz, Kurt S., \*154  
 Penhos, J. C., \*348  
 Pereda, Santiago A., \*348  
 Perillie, Pasquale E., \*551  
 Perkal, Stuart, S18-25  
 Perkoff, Gerald T., \*444  
 Perlman, Lawrence V., \*156-157  
 Perrine, J., \*158  
 Petersson, Birger, \*551  
 Pettit, George, \*246  
 Pfeiffer, E. F., S12  
 Phear, David, \*76  
 Pick, Ruth, \*77  
 Pickens, James M., 393-396  
 Pieroni, Romulo R., \*159  
 Pirani, Conrad L., \*440  
 Poe, Robert H., \*444  
 Pogátsa, Gábor, S16-18  
 Pokrajac, Niksa, \*78  
 Pollack, Herbert, 144, \*156-157  
 Pomeranze, Julius, \*553  
 Porter, Edith, \*250  
 Post, Richard H., 56-65, 287-290  
 Pote, William W. H., Jr., S132-135  
 Poucher, Russell L., S132-135  
 Presley, Sophie J., \*444  
 Proper, George, \*346  
 Ptacek, Edward D., 412-418  
 Pyle, Hugh M., 261-270, S34-35

## Q

Quaade, Flemming, \*444, \*444

## R

Rabkin, Mitchell T., \*444  
 Radding, Robert S., \*348, \*348, \*551, \*551-552  
 Rajalakshmi, S., \*76  
 Rakow, Robert R., \*546-547  
 Randle, P. J., \*76  
 Ranke, Eugene J., \*444  
 Rasmussen, H., \*76  
 Rauda, Vija, \*77-78  
 Ray, B. S., 469-470  
 R-Candela, J. L., \*440  
 R-Candela, R., \*440  
 Reaven, C., \*552  
 Recant, Lillian, S13, S139  
 Redfern, Earl, \*160  
 Reid, William M., \*250  
 Reisler, David M., 171-178  
 ReMine, William H., \*74-75

Renold, Albert E., \*78, \*158, \*249, \*550  
 Richards, J. G., \*72  
 Rick, W., \*75  
 Ricketts, Henry T., 150  
 Riddick, Frank A., Jr., 171-178  
 Ringler, I., \*158  
 Rivera, Evelyn M., \*250  
 Robb, Patricia, \*157  
 Roberts, H. J., \*250  
 Robinson, B. H. B., \*348  
 Robson, J. S., 291-295  
 Rodriguez, R. R., \*156  
 Roediger, Paul, \*441  
 Rony, Hugo R., \*157  
 Root, Howard F., \*77  
 Root, M. A., 83-90  
 Rose, F. Clifford, \*250  
 Rose, Herbert G., 192-196  
 Rosen, David A., 402-411  
 Rosen, Richard G., \*250  
 Rosenbaum, Louis, 375-377  
 Ross, Alexander T., \*348  
 Rossano, P., \*348  
 Rothman, Stephen, \*151  
 Routledge, J. H., 514-518  
 Rubin, Alan, \*349  
 Rubricius, Jeanette, \*157-158  
 Rudnick, Paul A., 533-543  
 Rudolf, Arnold J., \*249  
 Rupp, Joseph J., \*250, \*344  
 Ryder, Jill A., \*157

## S

Sabour, M. S., 291-295  
 Sadow, H. S., \*349  
 Samaan, N., \*77  
 Samols, Ellis, \*157  
 Sandberg, A. A., \*350  
 Sarcione, Edward J., \*550, \*552-553  
 Sarma, D. S. R., \*76  
 Sarma, P. S., \*76  
 Sato, T., 44-48  
 Schein, Clarence J., \*444  
 Schepens, Charles L., 465-469  
 Schmukler, Morton, 23-30  
 Schnall, Charles, \*76  
 Schneierson, S. Stanley, \*349  
 Scholz, Donald A., \*74-75  
 Schwartz, Robert, \*443-444  
 Schwarz, Klaus, \*443  
 Sciales, William J., \*352  
 Seftel, H. C., \*251  
 Segal, Stanton, \*157  
 Segre, Eugene J., \*552  
 Segura, E. T., \*342  
 Selby, John B., \*349  
 Seltzer, Holbrook S., \*349, S11-12, S13, S73, S141  
 Sen, A. K., \*349, \*349  
 Senior, B., \*77  
 Sexton, Richard C., Jr., \*350  
 Shamoian, Charles A., \*343, \*546  
 Shapiro, Alvin P., \*251  
 Shaw, Charles E., Jr., 23-30  
 Sheldon, H., 378-387  
 Shibolet, S., \*342

## DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
 March-April, 83-164

May-June, 165-260  
 July-August, 261-360

September-October, 361-460  
 November-December, 461-562

Volume II Supplement, 1-150



AUTHOR INDEX 1962

49, \*550

Shipp, Joseph C., S13, S69-73, S74, S93, S130  
 Shreeve, Walton W., \*157  
 Shuttleworth, John S., \*548  
 Sidbury, James B., \*547  
 Siegman, Felix, \*547  
 Sieker, H. O., \*74  
 Silagy, Joseph M., \*552  
 Silver, Abraham A., \*350, \*350  
 Silverstein, Murray N., \*350  
 Silverstone, Felix A., \*157-158  
 Simon, Kenneth A., \*552  
 Simons, Bryan E., Jr., 371-374  
 Simpson, Nancy E., 329-333  
 Sines, Lloyd K., \*548  
 Singer, David L., \*251  
 Singleton, A. O., Jr., \*552  
 Sjögren, Björn, 479-481  
 Skoryna, Stanley C., \*75  
 Slanetz, Charles A., Jr., \*156  
 Slater, J. D. H., \*77  
 Slaunwhite, W. R., Jr., \*350  
 Small, Jean L., \*251  
 Smetana, Hans F., \*552  
 Smith, Clement A., \*249  
 Smith, Kendrick, \*77  
 Smith, T. C., \*158  
 Smithies, O., 329-333  
 Sokal, Joseph E., \*550, \*552-553  
 Sokol, E. Marvin, \*158  
 Solomons, Edward, \*157-158  
 Soothill, John F., \*440  
 Sowton, Edgar, \*251  
 Spitzer, John J., 222-226, \*347, \*548-549  
 Sprague, Randall G., 388-392, 436-437, 491-494, S41, S92, S121  
 Stafford, Winifred L., \*350  
 Stamler, Jeremiah, \*77  
 Starin, Irving, \*156  
 Stauffer, J. Marvin, \*251, \*350  
 Steiner, Donald F., \*77-78  
 Steiner, R. E., 482-483  
 Steiness, Ib, \*350-351, \*351  
 Steinke, Jurgen, \*158, \*347, \*550-551, S43  
 Sterky, Göran C. G., 109-117  
 Stetten, DeWitt, Jr., 271-280  
 Stevenson, J. A. F., 321-328  
 Stewart, J. T., \*547  
 Stewart, Robert C., \*251  
 Stillman, Daphne, \*77  
 Stimson, William H., S146  
 Stobo, E. A., \*344-345  
 Stowers, J. M., \*252, S127-130  
 Strickland, William, \*73  
 Striebel, James L., 527-532  
 Strong, Jack B., Jr., \*158  
 Sube, John, \*155  
 Sullivan, James F., \*252  
 Sumi, S. M., \*252  
 Sutherland, James M., \*347-348  
 Suzuki, Kenui, \*441  
 Svanborg, A., \*152

2-553

12, S13,

3

Sweet, William H., 465-469  
 Szeinberg, Arieh, \*78

T

Taft, H. Pincus, S56  
 Tarrant, M. E., \*553  
 Taylor, E. Stewart, \*351  
 Taylor, Keith W., \*249  
 Teller, F. F., \*349  
 Thomas, Riley F., S74, S93  
 Thompson, George, S93-97  
 Thrush, Randolph S., 132-137  
 Tietze, Frank, \*553  
 Timm, D. L., \*347  
 Tinsman, Clarence A., 239-240  
 Tocci, Paul M., \*157  
 Tolstoi, Edward, \*553  
 Tomarelli, R. M., \*246  
 Tombropoulos, E. G., \*351  
 Tophøj, Else, \*160  
 Torres, José, \*346  
 Toussaint, Daniel, \*246-247, \*252, \*351  
 Traisman, Howard S., \*351  
 Tranquada, Robert E., 179-182, 183-191  
 Treuting, Theodore F., \*553  
 Tsapogas, M. J., \*553  
 Tucker, Francis C., \*153, \*248  
 Tunbridge, R. E., \*439  
 Turner, Naomi C., \*351  
 Turrill, Fred L., \*252  
 Tyberghein, Jean M., \*158  
 Tygstrup, Niels, \*553

U

Unger, Roger H., \*347, 371-374, S15, S140  
 Urbach, Stuart, \*441, \*549  
 Urrutia, Guillermo, 318-320

V

Vallance-Owen, J., \*351, \*352  
 Van Creveld, S., \*75  
 Van Gool, J., \*158-159  
 Vance, Vernon K., 318-320, \*550  
 Verner, John V., Jr., \*352  
 Villegas-Cinco, Aurora, \*352  
 Visintine, Robert E., \*346  
 Vlahos, Efstratios, \*546-547  
 Volk, Bruno W., \*75-76, 426-435, S2-10, S101, S121, S130  
 von Euler, U. S., \*159  
 Vranic, M., \*78

W

Wagle, Shreepad R., \*159  
 Wahlberg, Fredrik, \*352  
 Wajchenberg, Bernardo L., \*159

Wakim, Khalil G., \*350  
 Walcott, George, \*159  
 Walker, Geoffrey, \*346  
 Walker, Robert S., S56  
 Watkins, M. L., \*345-346  
 Weaver, J. A., 91-95  
 Weber, George, \*159  
 Webster, D. R., \*75  
 Wehrmacher, William H., \*78  
 Weil, William B., Jr., \*342  
 Weinberg, Arnold N., \*159-160  
 Weinstein, Ira, \*345-346  
 Weisenfeld, Shirley, \*154  
 Weiss, A., \*352  
 Weller, Charles, \*160, \*249  
 Werkö, L., \*152  
 Wertheimer, H. Ernst, 422-425  
 West, Kelly M., \*160  
 Wheeler, Anne H., \*550  
 Whichelow, M. J., \*72, 281-286, S43-49  
 White, Leslie L. R., \*353  
 Whitehouse, Fred W., \*160  
 Whitney, J. E., \*353  
 Widdas, W. F., \*349, \*349  
 Wildberger, Henry L., S42, S92  
 Wilkerson, Hugh L. C., 53-55, 204-208, \*252  
 Wilks, Helen M., S50-55  
 Will, L., \*158  
 Williams, Hibbard E., \*247  
 Williams, Robert H., \*77-78, \*245, S146  
 Williamson, Joseph R., 101-104, \*353, \*353  
 Wilson, D. Laurence, 402-411  
 Wilson, J. D., \*440  
 Winegrad, Albert I., 378-387, \*546, S42, S121  
 Wishinsky, Henry, S18-25, S93-97, S147  
 Wolff, O. H., \*550  
 Wollaege, Eric E., 388-392  
 Wolter, J. Reimer, 126-131  
 Wood, Francis C., Jr., \*78, S146, S147  
 Wooten, Richard L., \*353  
 Wrenshall, C. A., 236-239  
 Wright, David, S103-115  
 Wright, Peter H., 519-526, \*553  
 Wyngaarden, James B., \*441  
 Wynn, Victor, \*549, \*549-550

Y

Yalow, Rosalyn S., \*151, \*160  
 Yamauchi, M., 44-48  
 Yue, Kenneth T. N., \*160, \*248

Z

Zachariah, P., \*78  
 Zacks, S. I., \*353  
 Zak, Sylvia, \*248  
 Zetterstrom, R., \*72  
 Zierler, Kenneth L., \*245  
 Zintel, Harold A., \*250

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82  
 March-April, 83-164

May-June, 165-260  
 July-August, 261-360  
 Volume II Supplement, 1-150

September-October, 361-460  
 November-December, 461-562

## Reviewers

The Editors of *DIABETES: The Journal of the American Diabetes Association* are grateful to the following persons who reviewed books during the year 1962; or who, although not members of the Editorial Board, evaluated scientific contributions to the Journal.

### BOOKS

Deaconess Maude Behrman, Atlantic City	Alexander Marble, M.D., Boston
Harold Brandaleone, M.D., New York	Jean Mayer, Ph.D., D.Sc., Boston
James W. Craig, M.D., Cleveland	Peter E. Stokes, M.D., New York
Martin G. Goldner, M.D., New York	Edward Tolstoi, M.D., New York
Philip M. LeCompte, M.D., Boston	Robert C. Warner, M.D., New York
Gerald A. Wrenshall, Ph.D., Toronto	

### MANUSCRIPTS

James Ashmore, Ph.D., Indianapolis	W. Stanley Hartroft, M.D., Ph.D., Toronto
Joseph T. Beardwood, Jr., M.D., Philadelphia	Paul E. Lacy, M.D., Ph.D., St. Louis
Bernard Becker, M.D., St. Louis	Leland S. McKittrick, M.D., Brookline, Mass.
James Berkman, M.D., New Hyde Park, New York	Milton Mendlowitz, M.D., New York
Solomon A. Berson, M.D., New York	Vaun A. Newill, M.D., Cleveland
James M. B. Bloodworth, Jr., M.D., Madison	Mary A. Root, Ph.D., Indianapolis
Oscar Bodansky, M.D., New York	Harvey S. Sadow, Ph.D., New York
Arthur R. Colwell, Jr., M.D., Wilmette, Illinois	Holbrooke S. Seltzer, M.D., Dallas
Arthur R. Colwell, Sr., M.D., Chicago	Ethan A. H. Sims, M.D., Burlington, Vermont
Jerome W. Conn, M.D., Ann Arbor	Arthur G. Steinberg, Ph.D., Philadelphia
Norman Deane, M.D., New York	Priscilla White, M.D., Boston
Harold I. Farber, M.D., Reading, Pennsylvania	Arne N. Wick, Ph.D., San Diego
James B. Field, M.D., Bethesda, Maryland	Albert I. Winegrad, M.D., Philadelphia
Kenneth Zierler, M.D., Baltimore	

